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ABSTRACT
Microfabricated Fluidic Devices for Biological Assays and Bioelectronics
Anna V. Bickham
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Microfluidics miniaturizes many benchtop processes and provides advantages of low
cost, reduced reagent usage, process integration, and faster analyses. Microfluidic devices have
been fabricated from a wide variety of materials and methods for many applications. This
dissertation describes four such examples, each employing different features and fabrication
methods or materials in order to achieve their respective goals.
In the first example of microfluidic applications in this dissertation, thermoplastics are
hot embossed to form t-shaped channels for microchip electrophoresis. These devices are used to
separate six preterm birth (PTB) biomarkers and establish a limit of detection for each. The next
chapter describes 3D printed devices with reversed-phase monoliths for solid-phase extraction
and on-chip fluorescent labeling of PTB biomarkers. I demonstrate the optimization of the
monolith and selective retention of nine PTB biomarkers, the first microchip study to perform an
analysis on this entire panel. The third project describes the iterative design and fabrication of
glass/polydimethylsiloxane (PDMS) devices with gold and nickel electrodes for the selfassembly of DNA nanotubes for site-selective placement of nanowires. Simple flow channels
and “patch electrode” devices were successfully used, and DNA seeding was achieved on gold
electrodes. Finally, a 3D printed device for cancer drug screening was developed as a
replacement for one previously fabricated in PDMS. Devices of increasing complexity were
fabricated, and those tested found to give good control over fluid flow for multiple inlets and
valves.
Although the applications and methods of these projects are varied, the work in this
dissertation demonstrates the potential of microfluidics in several fields, particularly for
diagnostics, therapeutics, and nanoelectronics. Furthermore, it demonstrates the importance of
applying appropriate tools to each problem to gain specific advantages. Each of the described
devices has the potential for increased complexity and integration, which further emphasizes the
advantages of miniaturized analyses and the potential for microfluidics for analytical testing in
years to come.

Keywords: microfluidics, preterm birth, electrophoresis, solid-phase extraction, nanoelectronics,
cancer therapeutics, point-of-care, 3D printing, porous polymer monolith

ACKNOWLEDGEMENTS
First, I would like to thank my family for always being there for me, specifically my
parents for teaching me and helping me to become the person that I am, my siblings for always
being there when I need a friend, and my husband Bryce for all of his help and support.
I’d also like to thank my advisor, Adam Woolley, for all of the training and growth I’ve
had in his lab. I feel very fortunate to have been able to work with Adam and have appreciated
both his guidance and the freedom to follow through with my ideas while working in his lab.
Thanks also to Greg Nordin, whom I’ve also worked with closely the past few years. Greg has
been very supportive of my research and I appreciate the input he has provided. I’d also like to
thank the other faculty at BYU that have given me their time and support, particularly my other
committee members: Daniel Austin, Matthew Linford, Paul Farnsworth, and Ryan Kelly.
Next, I’d like to thank all of the amazing people I’ve been able to work with. Many of
them have become my friends and lightened the load including Mike Beauchamp, Ellen Parker,
Robert Hansen, Haifa Almughamsi, and many others. Additionally, few people are lucky enough
to work with their family, and I’ve been doubly lucky to work with my brother Jacob and my
husband Bryce for several years.
Finally, I’d like to thank the funding sources that have paid for my graduate work. I’ve
been supported by the National Institutes of Health (R01 EB006124 and R01 EB027096), the
National Science Foundation (Grant #1562729) and several awards provided by the BYU
Department of Chemistry and Biochemistry including the Nicholes-Maw New Graduate
Fellowship, J. Rex and Marcia A. Goates Graduate Fellowship, Roland K Robins Graduate
Research Fellowship, and Garth Lee Graduate Research Fellowship.

TABLE OF CONTENTS

LIST OF TABLES ........................................................................................................................ vii
LIST OF FIGURES ..................................................................................................................... viii
1.

INTRODUCTION ................................................................................................................... 1
1.1

Microfluidics .................................................................................................................... 1

1.2

Fabrication and Materials ................................................................................................. 2

1.2.1

PDMS........................................................................................................................ 2

1.2.2

Thermoplastics .......................................................................................................... 3

1.2.3

3D Printing ................................................................................................................ 4

1.3

2.

Microfluidic Methods and Features ................................................................................. 6

1.3.1

Microchip Electrophoresis ........................................................................................ 6

1.3.2

Porous Polymer Monoliths ....................................................................................... 8

1.3.3

Droplet Microfluidics................................................................................................ 9

1.3.4

Valves and Pumps ................................................................................................... 10

1.4

Dissertation Overview .................................................................................................... 11

1.5

References ...................................................................................................................... 12

MICROCHIP ELECTROPHORESIS SEPARATION OF A PANEL OF PRETERM BIRTH

BIOMARKERS ............................................................................................................................ 21
2.1

Introduction .................................................................................................................... 21

iv

2.2

3.

Materials and methods ................................................................................................... 24

2.2.1

Reagents and materials ........................................................................................... 24

2.2.2

Device fabrication ................................................................................................... 25

2.2.3

PTB biomarker preparation..................................................................................... 26

2.2.4

Instrumentation ....................................................................................................... 27

2.3

Results and Discussion ................................................................................................... 28

2.4

References ...................................................................................................................... 38

3D PRINTED MICROFLUIDIC DEVICES FOR SOLID-PHASE EXTRACTION AND

ON-CHIP FLUORESCENT LABELING OF PRETERM BIRTH RISK BIOMARKERS ........ 44

4.

3.1

Introduction .................................................................................................................... 44

3.2

Materials and Methods ................................................................................................... 47

3.2.1

Materials ................................................................................................................. 47

3.2.2

3D Printing .............................................................................................................. 48

3.2.3

Monolith Preparation .............................................................................................. 49

3.2.4

Experimental Setup ................................................................................................. 50

3.3

Results and Discussion ................................................................................................... 51

3.4

References ...................................................................................................................... 61

ITERATIVE DEVELOPMENT OF FLUIDIC DEVICES FOR BIOLOGICAL

APPLICATIONS .......................................................................................................................... 67
4.1

Introduction .................................................................................................................... 67

v

4.2

Device Design and Fabrication for Point-to-Point DNA Nanowire Assembly ............. 68

4.2.1

Introduction ............................................................................................................. 68

4.2.2

Materials and Methods ............................................................................................ 70

4.2.3

Results and Discussion ........................................................................................... 71

4.3

Design and Fabrication of Multi-Inlet Droplet Formation Devices for Cellular Drug

Testing ....................................................................................................................................... 77
4.3.1

Introduction ............................................................................................................. 77

4.3.2

Materials and Methods ............................................................................................ 78

4.3.3

Results and Discussion ........................................................................................... 80

4.4
5.

References ...................................................................................................................... 86

CONCLUSIONS AND FUTURE WORK ............................................................................ 90
5.1

PTB Biomarker Separations ........................................................................................... 90

5.2

Solid-Phase Extraction and On-Chip Labeling of PTB Biomarkers .............................. 92

5.3

Fluidic Devices for DNA Nanowire Growth and Characterization ............................... 94

5.4

3D Printed Multi-Inlet Droplet Generator Devices ........................................................ 96

5.5

Concluding Remarks ...................................................................................................... 99

5.6

References ...................................................................................................................... 99

vi

LIST OF TABLES

Table 2.1. Panel of nine PTB biomarkers and their molecular masses ........................................ 22
Table 2.2. Amino acid sequences for three PTB peptide biomarkers .......................................... 34
Table 2.3. Migration time, calibration curve linear regression (R2), and the mean LOD (all
determined from three different devices) for six PTB biomarkers ............................................... 36
Table 3.1 PTB biomarkers, their molecular masses, and a characterization of the hydrophobicity
of their amino acid composition ................................................................................................... 46

vii

LIST OF FIGURES

Figure 1.1. µCE device and electrode setup for voltage application ............................................. 7
Figure 2.1. Microfluidic device used for PTB biomarker separations ......................................... 25
Figure 2.2. Schematic of LIF detection instrumentation ............................................................. 27
Figure 2.3. µCE of FITC-Fer (100 nM) in untreated and photografted COC devices ................ 29
Figure 2.4. Comparison of CE and µCE separations ................................................................... 29
Figure 2.5. μCE of FITC‐labeled Fer (10 nM) and LF (60 nM) at 500 V/cm with different
running buffers .............................................................................................................................. 30
Figure 2.6. Fluorescence of 1 µM FITC as a function of pH in 25 mM acetate (pH 3-6),
phosphate (pH 6-8), and bicarbonate (pH 8-11) buffers ............................................................... 31
Figure 2.7. Resolution of Fer, P1, and LF with changing running buffer concentration ............. 31
Figure 2.8. Effect of voltage on PTB biomarker separations....................................................... 32
Figure 2.9. μCE of six PTB biomarkers labeled with FITC ........................................................ 33
Figure 2.10. Calibration curves for LOD determination for six PTB biomarkers ....................... 35
Figure 3.1. 3D printed microfluidic devices with monoliths for SPE and on-chip labeling
experiments ................................................................................................................................... 48
Figure 3.2. SEM images of monoliths in 3D printed microfluidic channels ................................ 53
Figure 3.3. Images of reversed-phase LMA monoliths during SPE ............................................ 56
Figure 3.4 SPE of Alexa Fluor and prelabeled PTB biomarkers on LMA reversed-phase
monoliths in 3D printed microfluidic devices .............................................................................. 58
Figure 3.5. SPE and on-chip fluorescent labeling of PTB biomarkers on LMA reversed-phase
monoliths....................................................................................................................................... 60

viii

Figure 4.1. Point-to-point attachment of DNA ............................................................................ 69
Figure 4.2. Schematic of the proposed fluidic device for DNA nanowire formation and
characterization ............................................................................................................................. 71
Figure 4.3. Microfluidic device fabrication for 3D DNA point-to-point attachment .................. 72
Figure 4.4. Patch electrode device designs for testing of DNA attachment and nanotube growth
on a metal surface ......................................................................................................................... 74
Figure 4.5. Confocal microscope images showing DNA seeded onto gold patch electrode
devices........................................................................................................................................... 75
Figure 4.6. Schematic of the addition of a PDMS layer to the patch electrode design and the
experimental procedure for DNA nanotube growth on these devices .......................................... 76
Figure 4.7. CAD designs of PDMS microfluidic devices for the flow of cells or other analytes
into an oil medium for droplet formation ..................................................................................... 80
Figure 4.8. Simple devices for testing experimental conditions transitioning from PDMS devices
to 3D printed valves and channels ................................................................................................ 82
Figure 4.9. Aqueous droplet emulsion flow through a 2-valve test device. (A) Photograph of the
emulsion flow through the right-side channels while flow in left-side channels is halted by
closing the left valve ..................................................................................................................... 83
Figure 4.10. Four-valve devices for testing of droplet formation by combining oil and aqueous
dye flows ....................................................................................................................................... 84
Figure 4.11. Three iterative designs for five-input (one oil, four analyte), eight-valve 3D printed
microfluidic devices ...................................................................................................................... 85
Figure 5.1. Schematics for 3D printed microchip electrophoresis devices .................................. 91
Figure 5.2. Photograph of 3D printed devices. ............................................................................ 93

ix

Figure 5.3. Schematics of microfluidic devices to increase the automation of a solid-phase
extraction system .......................................................................................................................... 94
Figure 5.4. Schematics of patch electrode devices with electrode junctions comprised of 5-10
µm gaps between gold and nickel electrodes on glass slides ....................................................... 95
Figure 5.5. Fabrication of integrated two-metal electrode fluidic devices for DNA nanotube
growth and nanowire formation and characterization .................................................................. 96
Figure 5.6. Schematics of the aqueous flow portions of multi-input droplet generator
microfluidic devices ...................................................................................................................... 98

x

1. INTRODUCTION *

1.1

Microfluidics
A consistent driving force for many scientific advances has been to develop cheaper,

easier, or more reliable technologies. Indeed, these specific ideas have interwoven many of the
advances that led to the development of microfluidics and the miniaturization of laboratory
processes to create lab-on-a-chip technologies and point-of-care diagnostics. Since the inception
of microfluidics over 30 years ago,1-3 the field has grown to encompass a variety of materials,
methods, and applications, with thousands of articles being published each year.
Microfluidics are a popular methodology for many analyses compared to conventional
benchtop methods due to the advantages of reduced cost, low reagent and sample consumption,
and faster analyses. These advantages are especially prominent in genetics, proteomics, cellular
assays, and point-of-care diagnostics.4 This range of applications has also resulted in an increase
in microfluidic device complexity as more processes are integrated onto a single platform,5-7 as
well as a number of commercialized point-of-care diagnostics.8-10
In this chapter, I discuss microfabrication methods and materials used for microfluidic
device creation with particular focus on those methods and materials which are applied in
chapters 2-4 of this dissertation. I also discuss a few of the experimental methods used to
perform the research in this dissertation. Although each of these topics could be discussed in

*

Section 1.2.3 and Figure 1.1 of this chapter are adapted with permission from the following:
- Nielsen, A. V.; Beauchamp, M. J.; Nordin, G. P.; Woolley, A. T. 3D printed microfluidics.
Annu. Rev. 2020, 13, DOI: 10.1146/annurev-anchem-091619-102649.
- Nielsen, A. V.; Woolley, A. T. Device fabrication and fluorescent labeling of preterm birth
biomarkers for microchip electrophoresis. In Clinical Applications of Capillary Electrophoresis:
Methods and Protocols; Phillips, T. M.; Ed.; New York, 2019; 1972, pp. 175-184.
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much greater detail than will be included here, each of these topics constitutes important
background information for the research I have performed.

1.2

Fabrication and Materials
Since many of the advantages of microfluidics are due to the reduced feature size in the

analytical devices, microfabrication method and material choice are a critical part of developing
a microfluidic device. Current methods to produce microfluidic devices include micromachining,
micromilling, hot embossing, injection molding, micropatterning, and 3D printing. These
methods have been applied to many materials including silicon, glass, silicones, plastics, and
paper. The variety, advantages, and reason for development of these materials have been
reviewed many times.11-13 Here, I will only discuss in detail those methods and materials which
are most relevant to the work presented in this dissertation: polydimethylsiloxane (PDMS),
thermoplastics, and 3D printing.

1.2.1

PDMS
Micropatterning of PDMS via soft lithography was first introduced in the late 1990s as an

alternative to difficult glass and silicon micromachining.14-15 Since then, the ease that PDMS
yields to microfabrication has made it the most popular material choice for microfluidics.
Fabrication via soft lithography involves cast molding, or the pouring of an unpolymerized
PDMS mixture onto a micropatterned surface. After forming to the surface shape, the polymer
can be cured to a solidified state and carefully peeled off of the surface, revealing a patterned
piece of PDMS.16 This method of device patterning is simple and allows a single mold to be
reused many times, reducing the cost of fabrication and exposure to harsh chemicals. If enclosed

2

features are desired, PDMS surfaces can be bonded to each other or to glass either reversibly
using van der Waals interactions or permanently via treatment with oxygen plasma.16
PDMS is a useful material for biological applications for several reasons in addition to
simple fabrication. First, PDMS is naturally biocompatible and gas permeable, lending the
material easily to cellular applications. Indeed, PDMS is the most popular material choice for
microfluidic-based cellular studies because many other materials lack these properties.
Additionally, the rubbery flexibility of PDMS has allowed for fabrication of membrane-based
valves and pumps for fluid control,17-19 which is not available in many other materials. Even if
the bulk of the microfluidic device is constructed from another material, many researchers embed
a PDMS membrane for valve construction,20-21 because PDMS so easily yields itself to the
flexibility and durability properties needed for such features.
Despite its wide usage within microfluidics, PDMS also comes with many
disadvantages.15,22 The polymer structure is prone to swelling in organic solvents and absorption
of small molecules. This is especially detrimental for applications that require long analysis
times or in which analyte concentrations are already low. Additionally, the process of soft
lithography is relatively manual, lending itself well to prototyping but not industrial production.23
This, in combination with a lack of device feature and interfacing standardization, has resulted in
a large number of microfluidic applications which are unable to reach a marketable status
because the manufacturing hurdle is too great to surpass.24

1.2.2

Thermoplastics
Around the same time as PDMS was first used, plastic materials were also making their

debut to simplify microfluidic device fabrication. Some of the earliest thermoplastic microfluidic
devices and fabrication methods included hot embossing of poly(methyl methacrylate)
3

(PMMA),25 injection molding of an acrylic copolymer,26 and laser photoablation of polystyrene,
polycarbonate, cellulose acetate, and poly(ethylene terephthalate).27 Since these early studies, a
large variety of other thermoplastics including cyclic olefin (co)polymer, polyethylene,
polypropylene, polyvinyl chloride, polyamide, polysulfone, polylactic acid,
polytetrafluoroethylene, polyetherketone, and acrylonitrile butadiene styrene and fabrication
methods including photolithography, etching, sputtering, micromilling, and CNC machining
have been used to create microfluidic devices.28
One of the greatest advantages of thermoplastic microfluidics is the variety of plastics
available. In addition to those plastics already mentioned, advances are being made with new and
more versatile materials.29-31 This variety has allowed each application to be matched to the best
suited material, thus easing the transition of many macro-plastic processes, particularly
biological applications, into the realm of microfluidics.22,32 Unfortunately, material matching has
also resulted in insufficient standardization in fabrication and fluidic design, which can
complicate commercialization. However, the use of thermoplastics greatly eases the transition of
many microfluidic applications into industrial-scale production,33 and thermoplastics continue to
be popular microfluidic device materials.

1.2.3

3D Printing
One technique that has recently gained traction for fabricating microdevices is 3D

printing, which offers several advantages over traditional fabrication techniques. Designs for 3D
prints are easily edited and reprinted, thus allowing for testing-based optimization. Additionally,
3D printed devices do not require a cleanroom fabrication environment. The consumables for 3D
printing are often only the resin and solvent to remove support materials, so costs can be low.
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Finally, 3D printing can fully utilize all three dimensions in device architecture, which should
allow unique capabilities to be realized.
There are many types of 3D printers commercially available which can print fluidic
features >200 µm including using stereolithography (SLA), PolyJet (PJ), or fused deposition
modeling (FDM) 3D printers. Many excellent reviews are available describing the advantages of
each of these printing types.34-36 For many 3D printers, particularly for PJ and FDM, millifluidic
features are the smallest that the printer is capable of producing.37 Though many manufacturers
advertise <100-μm resolution, deliverable fluidic feature size is typically many times larger than
that. This is particularly true for internal features, which are significantly more difficult to create
than surface structures. This discrepancy primarily exists because the creation of tiny features is
not only dependent upon printer specifications (i.e., motor step size, nozzle diameter, pixel size,
etc.), but also on the print material, the location and shape of the fluidic features being printed,
and a host of parameters specific to the printer type (e.g., infill rate, light source power and
wavelength, motor speed, etc.).
One of the most promising areas for 3D printing microfluidic devices involves using
digital light processing (DLP)-based SLA. DLP-SLA functions by photopolymerizing a liquid
polymer resin, one layer at a time, to form a 3D object. The polymer resin usually consists of a
monomer, photoinitiator, and UV absorber. It is important that the latter two components be
spectrally matched to the DLP light source, both to allow effective polymerization of the resin
and to limit light penetration into void regions to allow formation of small, enclosed features.38
Several groups have successfully leveraged DLP-SLA light sources39-42 or custom printers and
printing materials39,43-44 to embed microfluidic structures with features routinely <50 μm. At
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present, spectral matching of a DLP-SLA printer with the printing material is the only 3D
printing method able to achieve truly microfluidic devices.

1.3

Microfluidic Methods and Features
Because microfluidic devices have been developed for such a wide variety of

applications, a large number of methods and features have also been developed to accomplish
these goals. Some of these tools can be incorporated using only the channel geometry while
others require external connections or additional device processing to add a structure prior to
usage. A few microfluidic methods and features which are most relevant to the work in this
dissertation are discussed here, including microchip electrophoresis, porous polymer monoliths,
droplet microfluidics, and valves and pumps.

1.3.1

Microchip Electrophoresis
Microchip electrophoresis (µCE), a miniaturized electrophoretic separation method, was

one of the earliest applications of microfluidics.45 The miniaturized form of capillary
electrophoresis (CE), µCE is considered to be more convenient and simple than the benchtop
form, offering potential advantages of portability, high-throughput, and cost effectiveness.46
Additionally, the injection volume to perform a µCE separation is very small, allowing analysis
of precious samples. However, some analytes and microchip materials are more prone to
adsorption, making detection of these small sample volumes more difficult.47 Furthermore, the
reduced channel length compared to a traditional CE capillary can lead to a reduction in
separation efficiency, making it more difficult to analyze complex samples.48

6

Similar to CE, analytes in µCE are primarily separated by size and charge. Figure 1.1
shows a typical µCE setup in which a simple t-shaped device is filled with buffer. Sample is
injected when a low electric field is applied, and a small plug in the intersection is separated
when a high electric field is applied to the separation channel. Analyte velocity is affected by the
applied separation electric field, and the best separation efficiencies are usually achieved by
maximizing the applied voltage while minimizing Joule heating.45,49 Analyte mobility is further
affected via electroosmotic flow by the surface properties of the separation channel, as
determined by the device material and separation buffer. However, the electroosmotic flow can
be altered by applying a surface modification. Dynamic coatings are more popular for plastic
devices and are applied by adding a polymer or surfactant to the running buffer. Permanent
modifications are more stable and don’t require replenishing, but they are more laborious to
apply. These permanent modifications are more commonly used for glass and silicon devices

Figure 1.1. µCE device and electrode setup for voltage application. (A) Photograph of device
and Pt electrode placement. (B) Schematic for injection voltage application. (C) Schematic for
separation voltage application. Voltages other than those pictured here (500 and 1500 V) may be
used, but the injection voltage should be lower than the separation voltage. Arrows indicate the
flow direction of the green sample.
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because they are generally considered less disposable and the surface modification chemistries
are well known.47
µCE has been applied in the separation of many molecules including lipids,
carbohydrates, nucleic acids, proteins, small molecules, and even cells for applications in
biomarker analyses, pharmaceuticals, and biomedical research.46,50-52 The broad usefulness of
µCE has led to marketing of both µCE devices and complete µCE systems by several companies
including PerkinElmer (LabChip), Shimadzu (MultiNA), and Agilent (2100 Bioanalyzer), .
These applications have also made µCE a good choice for fast, quantitative separation and
detection of analytes.53

1.3.2

Porous Polymer Monoliths
Monoliths are porous polymer structures that can be polymerized inside a capillary or

microfluidic channel as a solid support structure for analytical applications. Monoliths are
usually fabricated from either silica or organic polymers54 and were originally developed for
chromatography. Beyond chromatographic separation, monoliths have also found usage for
extraction, microreactors (catalysis), and as scaffolds for tissue engineering.55
Monoliths are often advantageous as a replacement for a packed bead bed because they
allow for in situ preparation, low back pressures, and no frit requirement due to secure wall
anchoring.54,56 Their most common disadvantages include monomer-dependent swelling in
organic solvents and column capacity compared to other sorbent materials like packed silica
beads.56-57 However, this surface area difference is mainly due to analyte mass transfer ability,
meaning that monoliths usually perform better for large mass molecules while packed beds are
better for small molecules.
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Monolith morphology is characterized primarily by pore size (macro- and meso-pores)
and polymerized nodules (size and shape). This characterization is significant because
morphology can affect the efficiency of the analytical process being performed.58 For example,
the presence of mesopores may enhance the performance of a chromatographic separation but
hinder the effectiveness of confocal microscope imaging. While morphology can be tuned by
changing the monolith recipe, it is important that characterization of a particular recipe only
occur if the monolith has been treated under the same conditions as it will be used for in
experiments; polymerization in a microchip or capillary can yield significantly different
morphological features than polymerization in bulk solutions or suspensions.56-57

1.3.3

Droplet Microfluidics
Droplet microfluidics is the use of reagent and sample droplets enclosed within another

fluidic phase, usually formed and manipulated inside of microfluidic channels. This branch of
microfluidics was originally developed in order to create a high-throughput system to perform
large number of analyses simultaneously as each droplet functions as an individual, isolated
reaction chamber.59-60 Because the droplets have a high surface area-to-volume ratio, chemical
reactions can be performed faster due to rapid diffusion and heat and mass transfer rates.61
Droplets can also be mixed, sorted, fused, split, or otherwise manipulated by flowing through
different channel geometries or exposure to an electromagnetic field.61
Many studies have been performed demonstrating the ability to generate different sizes
and numbers of droplets within microfluidic devices. These droplets can be created either
actively by utilizing an electric, magnetic, or centrifugal field, or passively by utilizing channel
geometry, fluid properties (velocity, viscosity, and surface tension), or device material properties
(wettability and surface tension).62 The most important feature is that the two fluid phases cannot
9

be miscible; two flows must have some kind of interfacial instability to allow droplet formation
rather than co-flow or mixing, and the fluid flow must be laminar.61
Droplet microfluidics have been applied to many fields including chemical kinetics,
protein crystallization, organic synthesis, nanoparticle synthesis, and microextraction.63-64
However, one of the most important applications of droplets is for single-cell analysis. Although
these single-cell assays sometimes require extra considerations to maintain cell viability (e.g.,
feeding, gas exchange, waste removal, etc.),65 droplets enable many studies into the genomic,
proteomic, epigenomic, metabolomic, and biophysical (mechanical and electrical) properties of
isolated cells.66-67 These single-cell analyses are particularly insightful as high-throughput, timedependent, or high-replicate experiments when coupled to a high-throughput detection method
such as barcoding.69-70

1.3.4

Valves and Pumps
Microfluidic integration often requires the increased fluid flow control achieved with on-

chip valves and pumps. A large number of valving methods have been applied to microfluidics
including piston, bubble, capillary, hydrogel, pneumatic, electrostatic, time-delayed, check, and
electrowetting,71-72 and most can also be placed and actuated in series to create fluid pumps.
Each valving method lends itself more easily to specific fabrication methods and materials, and
each gives specific advantages to corresponding applications.
The first pneumatic valves, termed “Quake valves,”17 were constructed from PDMS and
remain one of the most popular choices for microfluidic devices. However, other normally-open
pneumatic valve designs are used include the plunger valve,19 lateral deflection valve,73 and line
valve.74 Additionally, normally-closed valves such as doormat,75 curtain,76 or lifting-gate18
valves can be used if vacuum is used in place of pressure in the control channel.
10

As mentioned in Section 1.2.1, most pneumatic valves are fabricated from PDMS
because the material is flexible and durable enough to allow for repeated actuation of a thin
(often 5-15 µm) membrane. However, other materials can achieve similar results. For example,
the Nordin lab at BYU recently created 1-mm diameter lateral deflection valves in 3D printed
devices using a custom poly(ethylene glycol) diacrylate (PEGDA)-based resin.77 They have since
demonstrated the ability to shrink these valves to 300-µm diameter and to pack them tightly to
create mixer pumps.78 I anticipate future integration of these valves into several of the projects
described in this dissertation.

1.4

Dissertation Overview
The use of microfluidics offers the potential for many benchtop, diagnostic, and manual

processes to be miniaturized, automated, and integrated on a single platform. The number of
fabrication methods, materials, and applications that have been applied to microfluidics has only
scratched the surface of what may be possible in the future. This dissertation describes several
microfluidics-based projects that demonstrate these capabilities. Each utilizes different
microfabrication techniques to realize applications in biological assays or bioelectronics.
In Chapter 2, I describe the development of a microchip electrophoresis method to
separate six peptide and protein preterm birth (PTB) biomarkers. Several separation buffers and
applied voltages were tested to establish conditions that could include this many of the
biomarkers. Electrophoretic separations were performed in COC devices with a photografted
surface inside the channels to reduce electroosmotic flow. This separation was an important step
to detect multiple PTB biomarkers preliminary to creating a complete PTB diagnostic test.
In Chapter 3, the development of a reversed-phase monolith for the solid-phase extraction
of peptide and protein PTB biomarkers is described. The PTB biomarkers are selectively retained
11

on the monolith during flow through and on-chip labeling experiments. The microfluidic devices
used for this work were 3D printed using the custom 3D printer and resin described in the
literature.39 The work described in this chapter is also the first time all nine biomarkers in this
PTB risk biomarker panel have been used in a microchip analysis.
In Chapter 4, I describe the process of iterative improvements to a microfluidic device
design to build up to a complete, integrated device. I describe two different projects that
followed this approach and were performed in collaboration with other research institutions. The
first project involves the fabrication of fluidic devices that have embedded gold and nickel
electrodes for the seeding and growth of DNA nanotubes and their eventual metallization into
nanowires. The fluidic devices were fabricated from glass and PDMS with gold and nickel
electrodes for testing of the nanowire electrical properties. The second project involves the
transition of a PDMS droplet microfluidic device for high-throughput cancer drug testing to a 3D
printed design. This project highlights the design considerations and improvements inherent to
3D printing compared to conventional microfabrication.
In Chapter 5, I summarize conclusions from the previous three chapters. I also describe
promising future directions for each project for continued improvement and integration with
other microfluidic features.
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2. MICROCHIP ELECTROPHORESIS SEPARATION OF A PANEL OF
PRETERM BIRTH BIOMARKERS *

2.1

Introduction
Preterm birth (PTB) or birth before the 37th week of gestation is the leading cause of

pregnancy-related complications and infant death.1 The World Health Organization has
estimated that over one in ten births is preterm, resulting in over one million infant deaths every
year.2 In addition to the high mortality rates for preterm infants, many struggle with incomplete
development of vision, hearing, lungs, heart, or brain. While some of these complications can be
resolved with proper intensive care treatment, others will last for the infant’s entire life.3 The
cost to care for these complications was at least $26 billion in 2013 in the United States,4 and
these numbers have only increased in recent years.
Many PTB casualties are associated with incomplete development of vital organs.
However, it is possible to increase developmental rates in some cases prior to birth if given
enough advance notice to administer treatment. For example, treatment with antenatal
corticosteroids prior to birth can improve lung development and reduce preterm infant mortality
by over 370 thousand deaths annually.2,5 The challenge is predicting PTB risk before the onset of
early labor. While some factors such as environment, high blood pressure, a history of PTB,
diabetes, or multiple pregnancies (i.e., twins, triplets, etc.)6-9 are indicative of higher PTB risk,

*

This chapter is adapted with permission from:
Nielsen, A. V., Nielsen, J. B., Sonker, M., Knob, R., Sahore, V., Woolley, A. T. Microchip
electrophoresis separation of a panel of preterm birth biomarkers. Electrophoresis 2018, 39,
2300-2307.
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there are many cases in which none of these factors is present. Unfortunately, for many women,
the first indication of PTB risk is the occurrence of early contractions.
In addition to physical factors, many chemical factors have been studied10-13 in an attempt
to diagnose PTB risk early. Recently, Esplin et al.14 found three serum peptides indicative of
PTB risk. The combined detection of these three peptides and six previously identified protein
and peptide biomarkers9 (Table 2.1) at a gestational age of 28 weeks allowed for the diagnosis of
PTB risk with 87% selectivity and 81% specificity four weeks prior to the onset of early labor.
However, the method that Esplin et al. used to identify these biomarkers involved solvent
treatment to access the low-molecular-weight proteome, followed by LCMS analysis. This type
of analysis, though powerful, is difficult and expensive to automate, especially for large-scale
preparation of samples.15 Other approaches such as sandwich or competitive immunoassays are
similarly limited by difficulty in multiplexing, the lack of two regions for antibody recognition in
the smaller peptides, or lower sensitivity and specificity for competitive immunoassay.16 Thus,
Table 2.1. Panel of nine PTB biomarkers and their molecular masses.
PTB Biomarker

Abbreviation

Mass (kDa)

PTB Peptide 1

P1

2.0

Corticotropin releasing factor

CRF

2.7

PTB peptide 2

P2

4.2

PTB peptide 3

P3

4.2

Defensins

Def

3-6

Tumor necrosis factor-α receptor type 1

TNF

26

Lactoferrin

LF

80

Thrombin-antithrombin III

TAT

95-110

Ferritin

Fer

470
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an urgent, unmet need exists for a diagnostic platform capable of PTB biomarker analysis in a
clinical environment. Ideally, this platform would be inexpensive, easy to use, and robust while
allowing low limits of detection (LODs) even in a complex matrix.17
Microfluidics are uniquely situated to fill the needs posed for PTB biomarker analysis;
indeed, integrated microfluidics allow many laboratory-based techniques and processes to be
miniaturized onto a single platform.17-22 Additionally, integrated microfluidics require less
sample and reagent volumes than most benchtop methods, limit sample loss, and allow for
automation of complete analyses. The field of integrated microfluidic biomarker analysis has
been growing rapidly. Just in recent years, new microfluidic platforms for biomarker analysis
have emerged with capabilities for colorimetric or electrochemical assays,23-24 ELISA,25 and
other biosensors.26-27 However, a common disadvantage of most of these studies is that they were
only capable of analyzing a single analyte per device. Tang et al.’s work24 was an exception
where four cancer biomarkers were measured, but this analysis required off-chip sample
preparation and an array of sensors to achieve multiplexing.
In an effort to create an integrated microfluidic PTB biomarker analysis system capable
of multiplexing, the Woolley lab has previously demonstrated SPE enrichment of select PTB
biomarkers and integration of this system with microchip electrophoresis (µCE) for subsequent
separation.28-30 Additionally, the ability to capture and purify PTB biomarkers from blood serum
using immunoaffinity extraction coupled with µCE for subsequent separation has been
demonstrated.31 In each of these cases, studies were only performed with one or two biomarkers.
For greater sensitivity and specificity in PTB risk analysis to be realized, more biomarkers need
to be separated and analyzed.
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Here, I describe the development of a µCE method capable of separating six of the nine
PTB biomarkers in this panel. I found that the resolution between the biomarker peaks could be
influenced by the running buffer concentration and voltage. Additionally, LODs were
determined for each of the PTB biomarkers in the µCE separation. After future integration with
sample preparation steps, this µCE method should play a critical role in an integrated
microfluidic PTB risk diagnostic test and allow for multiplexed identification and quantification
of PTB biomarkers.

2.2

Materials and methods

2.2.1

Reagents and materials
The following chemicals were ordered from Sigma (St. Louis, MO): 2-

(cyclohexylamino)ethanesulfonic acid (CHES), hydroxypropyl cellulose (HPC; 106 Da),
poly(ethylene glycol) diacrylate (PEGDA; 575 Da), inhibitor remover beads, dimethyl sulfoxide
(DMSO), and benzoin methyl ether (BME). Fluorescein 5-isothiocyanate (FITC) was purchased
from Life Technologies (Carlsbad, CA). PTB biomarkers were obtained from the following
sources: ferritin (Fer) from EMD Millipore (Billerica, MA), lactoferrin (LF) from Sigma (St.
Louis, MO), PTB peptide 1 (P1) and PTB peptide 2 (P2) from Biomatik (Wilmington, DE),
corticotropin releasing factor (CRF) and FITC-labeled P1 from GenScript (Piscataway, NJ), and
tumor necrosis factor-α receptor type 1 (TNF) from ProSpec (East Brunswick, NJ). All solutions
were made with deionized water (18.3 MΩ•cm) from a Barnstead EASY-pure UV/UF system
(Dubuque, IA). Methanol was purchased from Macron (Center Valley, PA), sodium hydroxide
from Mallinckrodt Baker (Paris, KY), and sodium bicarbonate from Merck (Darmstadt,
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Germany). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), cyclohexane, and
Amicon ultra 0.5 mL centrifugal (3, 10, 30, and 50 kDa cutoff) filters were purchased from EMD
Millipore. Zeonor 1060R cyclic olefin copolymer (COC) was purchased in 1 and 2 mm thick
sheets (Zeon Chemicals; Louisville, KY) cut to 2.2×5 cm2 pieces with an industrial bandsaw.
Silicon wafers were from Fairchild (Phoenix, AZ) and S1805 photoresist came from MicroChem
(Westborough, MA).

2.2.2

Device fabrication
Fabrication of “T-shaped” microchips in COC was performed using methods described

previously. Briefly, silicon wafers were patterned and etched using standard photolithography
and etching techniques.32 The pattern was transferred into a 1 mm thick piece of COC, which
was subsequently bonded to a 2 mm thick piece of COC with corresponding reservoir holes
made with a drill press (Cameron; Sonora, CA).31,33 Finally, cyclohexane was applied to the
device edges to enhance bonding. Channel dimensions were approximately 20 µm tall × 50 µm
wide. A device photograph is given in Figure 2.1.

Figure 2.1. Microfluidic device used for PTB biomarker separations. (A) Device photograph. (B)
SEM of channel cross-section.
Prior to µCE experiments, COC device channels were coated using a photografting
method adapted from one used previously.29 PEGDA was filtered through inhibitor remover
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beads to remove the methyl ether hydroquinone polymerization inhibitor. A solution of 4%
PEGDA and 1% BME was made in a 50:50 v/v mixture of water and methanol. The channels
and reservoirs were filled with this solution, and the device was exposed to UV light (Uvitron;
West Springfield, MA) for 12 min then flushed twice with water to remove excess photografting
solution.

2.2.3

PTB biomarker preparation
To fluorescently label the PTB biomarkers, P1, P2, and CRF were dissolved in 10 mM

bicarbonate buffer (BCB, pH 10). FITC was dissolved at a concentration of 10 mM in DMSO
and added to the individual biomarker solutions such that the dye-to-biomarker molar ratio was
3:2, and these solutions were incubated overnight in the dark at 37°C. The other three biomarkers
(LF, TNF, and Fer) were labeled under similar conditions except they were incubated at room
temperature and with dye-to-biomarker molar ratios of 15:1, 20:1, and 30:1, respectively. All
biomarkers except P1 were then filtered in the Amicon cutoff filter most closely correlated to the
biomarker’s size. Each was filtered four times for 15 min at 14000 RPM to remove excess dye.
The dye-to-biomarker ratios were chosen based on visual inspection of the filtrate during
filtration; if most of the excess dye was not removed by the fourth iteration, the labeling dye-tobiomarker ratio was reduced. Although this was a simple method for determining an adequate
dye-to-biomarker labeling ratio, the visual inspection results were well correlated with µCE data.
Finally, the biomarkers were diluted in 1 mM BCB (pH 9) prior to µCE.
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2.2.4

Instrumentation
The LIF detection system (Figure 2.2) had a 488 nm laser (CrystaLaser; Reno, NV)

aimed into a Zeiss Axio Observer.A1 inverted microscope (Jena, Germany) fitted with a Chroma
ET-488 nm laser bandpass set (Rockingham, VT). Laser power exiting the 20× microscope
objective was 4.8 mW. The microscope was fitted with a Hamamatsu PMT (Bridgewater, NJ)
with a Stanford Research Systems SR-560 preamplifier (Sunnyvale, CA). Analog PMT voltage
signal was converted to digital using a NI USB-6212 analog-to-digital converter (National
Instruments; Austin, TX) and recorded at 20 Hz using LabVIEW software (National
Instruments). µCE voltages were controlled using two high voltage power supplies (Stanford
Research Systems) and a custom designed voltage switching box. Platinum electrodes ran from
this box to the microchip reservoirs to apply the injection and separation voltages. Microchips
were operated using pinched sample loading34 with a 60 s injection time as described
previously.35 Separation fluorescence signal was measured 2 cm down the channel from the
intersection. All separations were performed at room temperature.36-37

Figure 2.2. Schematic of LIF detection instrumentation involving a laser directed into a
microscope fitted with a laser bandpass filter set, with filter wavelengths corresponding to the laser
and fluorescence wavelengths. Fluorescent light exits the microscope and passes through a pinhole
into the PMT creating an analog signal, which is first amplified and then converted to digital in
the analog-to-digital converter (ADC). This digital signal is then recorded using LabVIEW
software on the computer.
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2.3

Results and Discussion
A critical component in developing a biomarker panel analysis for PTB risk is separation

and quantification of these analytes. Factors that typically affect an electrophoretic separation
include pH, buffer composition, surface properties, and analyte mobility. Each of these was
investigated to develop a separation of this PTB biomarker panel.
Initial µCE experiments had inconsistent EOF between different COC devices.
Specifically, sample continued to bleed into the separation channel from the injection arms,
rather than being pulled back into the reservoirs once the separation voltage was applied. This
flow was contrary to the expected direction of migration and was also observed by Sonker et
al.,29 who photografted the COC surface with PEGDA to yield more reproducible EOF. I used a
similar photografting method to that of Sonker et al. with two minor differences. First, the use of
a water-methanol solvent in the photografting mixture yielded more reliable results than using
just methanol as the solvent. Second, I used a 4% PEGDA solution; 3% PEGDA was not
sufficient to eliminate the undesired migration of analyte while 5% PEGDA tended to block the
channels and prevent fluid flow. While these COC devices are compatible with standard 2D
micromachining, I note that it is also feasible to 3D print microfluidic devices from PEGDA.38-40
These 3D printed devices may be appealing for future analyses to avoid this photografting step.
Figure 2.3 shows a comparison of µCE in photografted and untreated devices.
Electropherograms from photografted devices yielded a reproducible, symmetrical peak for Fer,
while untreated devices yielded inconsistent results and had a rising baseline. Results from
photografted devices were also comparable to electropherograms measured on a conventional
CE system (Figure 2.4), showing the viability of these µCE devices for accurate and
reproducible analyses.
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Figure 2.3. µCE of FITC-Fer (100 nM) in untreated and photografted COC devices. Buffer is 50
mM CHES (pH 9); separation at 500 V/cm.

Figure 2.4. Comparison of CE and µCE separations. (A) Alexa Fluor 488 TFP-ester (AF; Thermo
Fisher) labeled P1 (100 µM) and Fer (20 µM) separated in 25 mM phosphate buffer (pH 8) on a
Beckman Coulter P/ACE MDQ (Brea, CA) at -1000 V/cm in a fused silica capillary (50 µm
internal diameter, detection at 20 cm). Detection wavelength was 200 nm. (B) FITC labeled P1
(100 nM) and Fer (210 nM) separated in 25 mM HEPES buffer (pH 8) in a photografted COC
microchip at 350 V/cm. The CE migration order is inverted from µCE due to the silica capillary
EOF. The difference in detection concentrations is due to UV absorbance (CE) compared to
fluorescence (µCE) detection systems. This difference in detection systems is also why peaks for
DMSO and unlabeled Fer can be seen in conventional CE.
For optimization experiments, I used only a representative portion of the PTB biomarkers
in the separations. This simplified the electropherograms for both visualization and
quantification of results. Fer was chosen because, at 470 kDa, it is the largest biomarker.
Likewise, P1 was used in many of these experiments because it is the smallest biomarker (2.0
kDa). LF was chosen both for its large size (80 kDa) and high pI value; initial experiments found
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that biomarkers like LF and P2 with high pI values were more adsorptive to the microchannel
surfaces and difficult to fluorescently label than biomarkers with lower pI values.
To test the dependence of separation efficiency on pH, two of the biomarkers, Fer and
LF, were fluorescently labeled and separated in photografted COC devices at four different pHs
from 7 to 10 (Figure 2.5). Because FITC fluorescence intensity is pH dependent (Figure 2.6), this
range was chosen to encompass most of its fluorescent range. The results from these separations
indicate that photografting largely suppressed EOF, resulting in the running buffer pH having
little effect on separation efficiency. The most significant effect of running buffer pH was on the
resolution of the dye peaks at the beginning of the run. Notably, the resolution of these dye peaks
was greatest for the pH 8 and 10 runs. Likely, this difference is due to the higher ionic strength
of these buffers compared to those at pH 7 and 9, which originates from titrating the buffer with
greater amounts of NaOH to reach the desired pH. Differences in ionic strength were confirmed
by monitoring the electrical current through the microchip channels during each separation,
which revealed higher current for the pH 8 and 10 separations than the other two.

Figure 2.5. μCE of FITC‐labeled Fer (10 nM) and LF (60 nM) at 500 V/cm with different running
buffers: pH 7, 100 mM HEPES; pH 8, 100 mM HEPES; pH 9, 100 mM CHES; pH 10, 100 mM
CHES. Signals are offset for clarity.
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Figure 2.6. Fluorescence of 1 µM FITC as a function of pH in 25 mM acetate (pH 3-6), phosphate
(pH 6-8), and bicarbonate (pH 8-11) buffers. Signal was measured on a Nanodrop 3300
Fluorospectrometer (Thermo Fisher; Waltham, MA).
The results from Figure 2.5 suggested that PTB biomarker separations were affected by
ionic strength more than the pH of the running buffer between pH 7–10. To confirm this,
separations of three biomarkers (Fer, P1, and LF) were performed with different running buffer
concentrations (Figure 2.7). It was found that increasing the buffer concentration improved
resolution for P1 and LF while diminishing the resolution for Fer and P1. It was also found that
the resolution approached a maximum or minimum value as the buffer concentration continued
to increase. This meant that the P1-LF resolution could be improved to a certain point without
completely deteriorating the Fer-P1 resolution. However, using higher running buffer
concentrations also increased the electrical current in the microchannels, which could lead to

Figure 2.7. Resolution of Fer, P1, and LF with changing running buffer concentration. Separations
were performed in HEPES buffer (pH 8) at 500 V/cm.
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Joule heating and other deleterious effects. To balance improved P1-LF resolution with
reasonable electrical current, a running buffer concentration of 100 mM was used for later
experiments. While a resolution of 0.5 for P1-LF is enough to distinguish these peaks, it may not
be sufficient to precisely quantitate these two biomarkers.
Another factor known to affect electrophoretic separation resolution and Joule heating is
the applied voltage.41-42 Separations were performed with the same three PTB biomarkers (Fer,
P1, and LF) and 100 mM HEPES buffer having 0.5% HPC (pH 8) using different applied
voltages. Figure 2.8A shows that increasing the applied voltage did not significantly affect the
P1-LF resolution but did decrease the Fer-P1 resolution. As can be seen, if the applied voltage
was doubled, the Fer-P1 resolution decreased by about a factor of two. The added HPC in the
buffer increased viscosity and narrowed the biomarker peaks by reducing any residual
biomarker-microchannel surface interactions that persisted after photografting. This improved
the P1-LF resolution but resulted in closer Fer-P1 migration times, which degraded the Fer-P1
resolution.

Figure 2.8. Effect of electric field on PTB biomarker separations. (A) Resolution of Fer and P1,
and P1 and LF as a function of electric field. (B) Separation run time as a function of electric field.
Separations were performed in 100 mM HEPES (pH 8) with 0.05% HPC.
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Besides affecting peak resolution, increasing the applied electric field decreased the
migration times of all analytes, as expected (Figure 2.8B). Higher electric field allows for a PTB
analysis to be performed more quickly and limits the time in which diffusional band broadening
can occur. To balance these benefits with the decreasing Fer-P1 resolution, 500 V/cm was
applied to the microchannels in future separations. This allowed separation of the PTB
biomarkers in one minute while maintaining satisfactory resolution between the biomarker
peaks.
The conditions selected for the separation of the PTB biomarker panel were a
photografted COC microchip run at 500 V/cm with a 100 mM running buffer of any pH between
7 and 10 at room temperature. Using these conditions, it was possible to separate six of the PTB
biomarkers (Figure 2.9): Fer, P1, LF, P2, CRF, and TNF. This separation is significant because it
is the first µCE separation of most of the components of this biomarker panel. It is also
significant because of the large mass range of analytes in the panel—from 2 to 470 kDa. Finally,

Figure 2.9. μCE of six PTB biomarkers labeled with FITC: Fer, 60 nM; P2, 130 nM; P1, 10 nM;
CRF, 60 nM; LF, 60 nM; TNF, 140 nM. Running buffer was 100 mM CHES (pH 9) with 0.05%
HPC; separation at 500 V/cm.
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most protein µCE separations contain three or fewer (often model) analytes;42 this separation
contains three peptides in addition to three proteins that are implicated in PTB.
Several additional points arise from the electropherogram in Figure 2.9. First, P2
produced two peaks, which is attributed to an N-terminal asparagine (Table 2.2) that degrades in
water to aspartic acid. Although it is possible to synthetically block the N-terminus to prevent
this degradation, it was left uncapped to more closely simulate a clinical sample. Moreover, the
larger protein biomarkers had broader peaks than the smaller peptide biomarkers in the
electropherogram. This is likely due to the greater number of fluorescent labeling sites available,
resulting in a broader distribution of charges on these proteins. The LF peak in particular is broad
both because of this charge distribution and its high pI value, which makes it more prone to
microchip surface adsorption than the other biomarkers. Finally, peak overlap occurs in some
regions of the separation, which could hinder quantitation especially for real samples.
Importantly, upstream sample preparation steps prior to µCE can be integrated on-chip for
analyzing real samples. Indeed, CE data of serum samples after on-chip immunoaffinity
extraction were comparable to results obtained from the same biomarkers in buffer.31 Moreover,
upstream immunoaffinity extraction can be used to split a biomarker panel to have any
interfering biomarkers (i.e., CRF and LF) divided into separate µCE runs for easier quantitation.
Table 2.2. Amino acid sequences for three PTB peptide biomarkers.

PTB Peptide Biomarker
Amino Acid Sequence
P1
qlglpgppdvpdhaayhpf
P2
nvhsagaasrmnfrpgvlssrqlglpgppdvpdhaayhpf
P3
nvhsagaasrm(O)nfrpgvlssrqlglpgppdvpdhaayhpf

Of the nine PTB biomarkers in the panel,14 three were omitted from the final separation:
PTB peptide 3 (P3), defensins (Def), and thrombin-antithrombin III (TAT). P3 was excluded
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because its amino acid sequence is nearly identical to that of P2; the only difference is where P2
contains a methionine, P3 contains an oxidized methionine (Table 2.2). As this oxidation
contributes neither a significant charge nor mass difference to the peptide, P2 and P3 have
indistinguishable electrophoretic mobilities, and only one was included in the biomarker
separation. Def was excluded because it represents several different peptides;9 its
electropherogram had multiple peaks that interfered with the signal from other PTB biomarkers.
Members of the Woolley lab are working to identify which specific Def peptide has the best
diagnostic potential so it can be added to the biomarker separation. Finally, TAT was not
included in this separation because it is not available commercially, and it is difficult to form the
TAT complex under conditions where fluorescent labeling is also feasible. As appropriate
conditions are developed, this biomarker could be added to the separation.
It is important to know how the LOD of each PTB biomarker compares with PTB risk
levels. Peak height calibration curves were established for each biomarker on three different
microchips (Figure 2.10). An LOD, the concentration at which the measured signal was three

Figure 2.10. Calibration curves for LOD determination for six PTB biomarkers. Data from the
devices that yielded the lowest LOD for each biomarker are shown.
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times the standard deviation of the baseline noise, was calculated for each of these calibration
curves. As seen in Table 2.3, the LOD for each of the biomarkers is in the nanomolar range.
Except for P1, the trend is for the larger mass biomarkers to have a lower molar LOD. Likely,
this is because larger biomarkers such as Fer and LF have more primary amines for reaction with
FITC, resulting in multiple labels being incorporated per protein. In contrast, smaller biomarkers
such as P2 and CRF, which contain a single primary amine labeling site (the N-terminus), can
only incorporate one label.30 In addition, the LOD for P2 is significantly higher than that of the
other PTB biomarkers because its tertiary structure creates steric hindrance around the Nterminus, which reduces the FITC-labeling efficiency.44 Although the efficiency was improved
by heating the biomarker solution during labeling, P2 still has a higher LOD than the other
biomarkers.
Table 2.3. Migration time, calibration curve linear regression (R2), and the mean LOD (all
determined from three different devices) for six PTB biomarkers. PTB risk levels where known
are also given for reference. Running buffer was 100 mM HEPES (pH 8) with 0.05% HPC.
PTB
Biomarker

Migration
Time (s)

Calibration R2

LOD
(nM)

PTB Risk
Level (nM)

P1
P2
CRF
TNF
LF
Fer

36.7+2.0
34.7+1.6
44.4+4.3
61.5+3.6
47.8+3.1
31.4+1.3

0.97
0.99
0.92
0.99
0.97
0.96

3
190
90
30
6
1

*
*
0.075
0.06
3
0.040

Table 2.3 also lists the biomarker concentrations in maternal blood serum14 that are
indicative of PTB risk. The LODs are approaching PTB risk levels for some biomarkers, but they
are not as low as will be necessary for PTB risk analysis. Importantly, by using on-chip sample
preparation steps prior to separation of the biomarkers, detection of these PTB biomarkers below
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their risk levels should be possible. Using immunoaffinity extraction from blood serum31 and
solid phase extraction28-30 as described previously, six-fold and 50-fold preconcentrations,
respectively, should be achievable for a combined 300-fold enrichment of the biomarkers. These
enrichment factors should lower the biomarker LODs to near or below the risk level
concentrations. I also expect further improvement of preconcentration capabilities as these
components are integrated into a single device.
There is an urgent need for a fast and inexpensive PTB risk diagnostic. This need could
be met by developing a microfluidic device that integrates sample preparation with separation
and detection of PTB risk biomarkers. Here, I have focused on the separation and detection of a
panel of PTB biomarkers. I studied the dependence of peak resolution on the running buffer
concentration and electric field. The dependence required a balance of parameters to be
considered to improve the poorest resolution between peaks without significantly deteriorating
others. Furthermore, I demonstrated a µCE separation for six combined protein and peptide
biomarkers: the first performed on this PTB biomarker panel. Additional experiments should
make it possible to add other biomarkers to this separation. Some of the PTB biomarker LODs
are approaching PTB risk levels, but lower detection limits are still needed. It may be possible to
achieve this using CE-LIF or CE-MS, but these methods would require larger sample volumes
and external sample preparation prior to analysis. Using the current approach, lower biomarker
LODs could be achieved via integration of this µCE separation with upstream sample
preparation steps that extract, purify, and enrich biomarkers28-31 from maternal blood serum
samples. Additionally, biomarker LODs could be lowered by implementing sample stacking
prior to µCE,45-46 improving the labeling efficiency,44,47 or use of a brighter fluorescent label
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such as Alexa Fluor.48-49 Once developed, such an integrated device has broad potential to be
applied to many other clinical biomarker analyses.
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3. 3D PRINTED MICROFLUIDIC DEVICES FOR SOLID-PHASE
EXTRACTION AND ON-CHIP FLUORESCENT LABELING OF PRETERM
BIRTH RISK BIOMARKERS *

3.1

Introduction
Over the past 30 years, the field of microfluidics has established advantages of low

sample and reagent consumption, fast analyses, and cost-effectiveness compared to many
benchtop instruments and processes. These benefits are apparent in a variety of applications,
including biomarker,1 nucleic acid,2 organ-on-a-chip,3 single- and multi-cellular,4-5 polymerase
chain reaction,6 and biosensor7 analyses. Available microfabrication methods have previously
limited the design capabilities of these microfluidic devices,8 but the recent trend towards use of
3D printing has created new possibilities for researchers to miniaturize, iteratively customize,
and integrate more sample preparation and analysis methods into fluidic chips.9 Although the
commercial availability of 3D printers capable of producing <100-µm channels is still limited,10
this barrier can be breached to achieve enclosed, truly microfluidic features.11
For growing applications in microfluidics, there is a persistent need to detect lower
analyte concentrations. Indeed, the use of small sample volumes in microchannels has a major
influence on the approach needed for detection of analytes of interest.12 Often, lowering the
analyte limit of detection must begin during sample preparation by limiting losses and
implementing preconcentration. Although there are many methods for preconcentration,12 solid-

*

This chapter is adapted from:
Bickham, A. V.; Pang, C.; George, B. Q.; Topham, D. J.; Nordin, G. P.; Woolley, A. T. 3D
printed microfluidic devices for solid-phase extraction and on-chip fluorescent labeling of
preterm birth risk biomarkers. Anal. Chem. Submitted.
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phase extraction (SPE) is one of the most general ones, because it can be applied to relatively
larger sample volumes.13 Miniaturization of an SPE system allows for integration with other
analysis steps and can be simple, fast, and effective. Many different SPE systems have been
developed previously for microfluidic applications, including for analysis of alkaloids,14 metal
ions,15-16 nucleic acids,17-19 aromatic hydrocarbons,20 and phosphopeptides.21 These applications
often utilize a variety of SPE sorbent beds such as packed beads, micro- or nanofibers, porous
polymer monoliths, membranes, or other microstructures to achieve high surface areas and
appropriate chemical properties for effective extraction.17,22 Monoliths can be particularly useful
because of their ease of in situ fabrication and morphological tuning.23 Recent initial studies
utilized monoliths in 3D printed fluidic devices for hydrogen/deuterium exchange,24
immunoaffinity extraction,25 liquid chromatography,26 and SPE of alkyl esters on a gold
nanoparticle modified monolith.27 However, only for the immunoaffinity extraction were the 3D
printed channels truly microfluidic, with cross sections smaller than 100 x 100 µm2.
Each year, nearly 15 million infants are born prematurely, resulting in over 1 million
deaths worldwide from either the direct effects of preterm birth (PTB) or later complications,
such as respiratory difficulties or increased susceptibility to infection.28 The World Health
Organization has a number of recommended interventions to reduce mortality rates,28 but they
are mainly focused on care during labor and after delivery. In part, this is because no early
clinical assessment currently exists to give warning of an imminent PTB prior to the onset of
labor. Such an assessment may be possible with a panel of nine previously discovered protein
and peptide biomarkers,29 summarized in Table 3.1. Toward development of a PTB risk
assessment, some of these protein and peptide biomarkers have been evaluated in microfluidic

45

Table 3.1 PTB biomarkers, their molecular masses, and a characterization of the hydrophobicity
of their amino acid composition.
Amino Acid Characterization

Biomarker

Mass
(kDa)

Hydrophobic

Neutral

Hydrophilic

Peptide 1

2.0

58%

21%

21%

CRF

2.7

49%

20%

32%

Peptide 2

4.2

50%

30%

20%

Peptide 3

4.2

48%

30%

23%

Defensins

3-20

41±7%

24±5%

35±6%

TNF

26

38%

38%

24%

Lactoferrin

80

39%

35%

25%

TAT

120

39%

33%

28%

Ferritin

420

37%

33%

30%

devices for immunoaffinity extraction,25,30 electrophoretic separations,31-32 and SPE.33-34
However, this entire panel has not previously been evaluated in a microfluidic analysis format.
Here, I show the development of a reversed-phase monolith for SPE of PTB biomarkers.
These monoliths are photopolymerized within 3D printed microfluidic device channels, allowing
for easy and fast device fabrication. The SPE devices were evaluated for retention and elution of
nine PTB biomarkers as well as a fluorescent label, Alexa Fluor 532 NHS ester. Finally, these
3D printed microfluidic devices were tested, using the same nine PTB biomarker analytes, for
performing on-chip SPE and fluorescent labeling. Notably, these 3D printed devices and
reversed-phase monoliths are well-suited for SPE retention and elution of PTB biomarkers
during on-chip labeling. These results demonstrate nearly universal retention and elution
performance for SPE of a diverse panel of protein and peptide biomarkers, marking an important
step toward the development of a complete miniaturized PTB risk assessment.
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3.2

Materials and Methods

3.2.1

Materials
The following chemicals were ordered from Sigma (St. Louis, MO): poly(ethylene

glycol) diacrylate (PEGDA; MW 250 Da), phenylbis(2,4,6-trimethylenzoyl)phosphine oxide
(Irgacure 819), acetonitrile (ACN), 1-dodecanol, ethylene dimethacrylate (EDMA), lauryl
methacrylate (LMA), octyl methacrylate (OMA), 2,2-dimethoxy-2-phenylacetophenone
(DMPA), 3-(trimethoxysilyl)propyl methacrylate, and dimethyl sulfoxide (DMSO). PTB
biomarkers were purchased from the following sources: PTB peptides 1-3 (Biomatik,
Wilmington, DE), corticotropin-releasing factor (CRF, GenScript, Piscataway, NJ), defensins
(mixed human neutrophil peptides, Athens Research and Technology, Athens, GA), ferritin
(EMD Millipore, Billerica, MA), lactoferrin (Sigma), tumor necrosis factor-α receptor type 1
(TNF, ProSpec, East Brunswick, NJ), thrombin and antithrombin (Haematologic Technology,
Essex Junction, VT), and heparin (Alfa-Aesar, Haverhill, MA). Fluorescent labeling of
biomarkers was performed using Alexa Fluor 532 NHS ester (Thermo Fisher, Fair Lawn, NJ)
with filtering in Amicon Ultra 0.5 mL centrifugal cutoff filters (EMD Millipore). Bicarbonate
buffer (BCB, pH 10) was prepared using sodium bicarbonate from Merck (Darmstadt, Germany)
and sodium hydroxide from Mallinckrodt Baker (Paris, KY). 2-nitrophenyl phenyl sulfide (NPS,
TCI Chemicals, Portland, OR) and glass slides (25 mm x 75 mm x 1 mm; VWR, Center Valley,
PA) were purchased for 3D printing. Additional solvents of isopropyl alcohol (IPA) and toluene
came from Macron. Finally, all water was purified to 18.3 MΩ·cm prior to use (Barnstead
EASY-Pure UV/UF, Dubuque, IA).
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3.2.2

3D Printing
Microfluidic devices are designed in the freeware computer-aided design (CAD)

software, OpenSCAD (openscad.org); each print has 10-µm-thick layers and includes five
identical devices. The design is adapted from one used by Parker et al.25 A 6-pixel (46 µm) by 5layer (50 µm) channel connects a 2.7 mm diameter x 0.75 mm deep reservoir to a 1.1 mm
diameter horizontal port, into which PTFE tubing (0.022 in ID x 0.042 in OD; Cole Parmer,
Vernon Hills, IL) is inserted for the application of vacuum for flow through the channel. The
device also includes a 600 µm wide monolith polymerization window, placed 60 µm above the
channel.25 CAD designs of the devices can be seen in Figure 3.1A-B.

Figure 3.1. 3D printed microfluidic devices with monoliths for SPE and on-chip labeling
experiments. (A-B) Top- and side-views of the CAD design of 3D printed devices, which have
five identical channels (light blue) with reservoirs (yellow) and vacuum-attachment ports (gray).
A polymerization window (blue) also runs perpendicular through the device, 60 µm above the
channels. (C) Photograph of a 3D printed device. (D-E) SEM images of an LMA monolith
polymerized within a 70 x 50 µm2 channel, demonstrating wall adhesion and porosity.
Microfluidic devices were formed in a custom 3D printer with a 385 nm light source. The
development of this printer and corresponding custom resin, consisting of 2% NPS and 1%
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Irgacure 819 in PEGDA, have been described previously.11 The exposure time for each layer in
the bulk material was 600 ms with 200 ms less exposure in the 3 pixels (~22 µm) to the side of
and 3 layers (~30 µm) above the channel region to widen the channels (70 µm x 50 µm) beyond
the designed size, as detailed previously by Beauchamp et al.35 All 3D prints were exposed with
a measured optical irradiance of 21 mW·cm-2 in the image plane.

3.2.3

Monolith Preparation
Similar to previously described procedures,33-34,36 reversed-phase monolithic columns

were prepared using 1% DMPA photoinitiator in a mixture of monomer (LMA or OMA),
crosslinker (EDMA), and porogens (1-dodecanol and/or cyclohexanol). Initially, these mixtures
were polymerized in microcentrifuge tubes for 10 min under a UV lamp (Uvitron, West
Springfield, MA) to analyze the degree of photopolymerization in each mixture. Analysis was
performed by visual inspection. Once a suitable range of component compositions was identified
using this approach, mixtures were polymerized in 3D printed device channels, sectioned with a
razor blade and imaged using SEM25 (Helios Nanolab 600 FEI, Fisher), and, in some cases,
experimentally tested by performing SPE of a PTB biomarker. Each monolith formulation was
analyzed for flow when vacuum was applied; morphology of nodules and pores; and PTB
biomarker extraction, retention, and elution. These criteria allowed for a well-suited mixture to
be decided upon and used for SPE and on-chip labeling of all nine PTB biomarkers.
After polymerization of monoliths within the 3D printed device channels, PTFE tubing
was inserted into the horizontal port for each channel and affixed with hot glue, then IPA was
drawn by vacuum through each channel for a minimum of 30 min. Cleaning was complete when
a channel and monolith could be successfully brought to complete dryness by vacuum. If
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residual liquid could not be removed by vacuum, additional IPA, device heating to ~35 °C, and
vacuum were applied. Monoliths in microfluidic devices prepared in this manner could then be
stored under ambient conditions until use.

3.2.4

Experimental Setup
PTB biomarkers were fluorescently labeled and filtered using previously described

procedures32,37 for prelabeled biomarker experiments. Thrombin-antithrombin complex (TAT)
was prepared 24 h prior to fluorescent labeling.32 For on-chip labeling experiments, PTB
biomarkers were diluted to the desired concentration in 10 mM BCB.
SPE experiments were performed in a previously described microscope setup for laserinduced fluorescence detection.25,37 Fluorescence images were collected with either a
Photometrics Cool-SNAP HQ2 CCD camera (Tucson, AZ) or a Hamamatsu ORCA-Fusion
CMOS camera (Bridgewater, NJ). Prior to biomarker extraction, a monolith was prepared by
adding IPA to the reservoir and allowing the channel to fill to the monolith by capillary action.
Next, the IPA was replaced with 10 mM BCB (pH 10) and vacuum was applied for 3 min. Then,
the liquid in the reservoir was replaced with 30% ACN (in 10 mM BCB), with vacuum
application for 90 s. Finally, the same was done with 90% ACN for another 90 s. This process of
flowing buffer, 30% ACN, and 90% ACN was repeated three times to clean and equilibrate the
channel. The flow rate was estimated to be 0.5-1 µL/min.
After equilibration, SPE experiments were performed. For prelabeled biomarkers,
vacuum was used to drive the following flow steps: BCB for 3 min, sample loading for 90 s,
BCB buffer rinse three times for 90 s each, 30% ACN for 90 s, and 90% ACN for 90 s. Although
most analytes were tested at several concentrations, the following concentrations were used for
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each analyte for the reported data: ferritin, 10 nM; TNF, 100 nM; peptide 1, 500 nM; defensins,
200 nM; CRF, peptides 2-3, TAT, and lactoferrin 1 µM; and Alexa Fluor, 2 µM. For on-chip
labeling experiments, a similar procedure was performed except two loading steps were
performed (PTB biomarker for 90 s, then Alexa Fluor labeling solution for 90 s) followed by a
30 min incubation prior to the buffer rinse. During the incubation time, the reservoir was refilled
with labeling solution as needed to prevent evaporative drying. For the reported data, the
following concentrations were used for each analyte: peptide 1, 500 nM; CRF, 1 µM; peptides 23, 600 nM; defensins, 200 nM; lactoferrin, 60 nM; TNF, 100 nM; TAT and ferritin, 50 nM; and
Alexa Fluor, 20 µM.
After each flow step, a fluorescence image was captured using 200 ms exposure (for both
detectors). All images were analyzed using Image J (NIH; imagej.nih.gov) to obtain the
fluorescent signal present on the monolith after each step of the process. The background signal
was subtracted from each, then the values were normalized to the signal after sample loading for
each experiment. Average signals from three replicates for each experiment are reported.

3.3

Results and Discussion
3D printed microfluidic devices for SPE were based on a design used previously by

Parker et al.25 However, the design was changed slightly by creating a horizontal port for
attachment of external tubing, which allowed for easier interfacing with vacuum to drive fluid
flow (Figure 3.1A-C). Because 3D printing was used for device fabrication, design modifications
were straightforward to apply; the CAD design could be edited, and new devices could be 3D
printed in less than 30 min.
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Although several similar reversed-phase monolith formulations have been reported
previously,33-34,36 a new formulation was developed for these SPE experiments both to avoid the
use of Tween-20 and to improve formation consistency. For initial development of the new
monolith, a number of mixtures containing OMA (10-28%), EDMA (7-25%), 1-dodecanol (4570%), cyclohexanol (0-12%), and DMPA (1%) were mixed and polymerized in microcentrifuge
tubes. Visual inspection found that mixtures containing too high of a porogen content (not
enough monomer and crosslinker) were viscous and transparent, while mixtures that did not
contain enough porogens (too much monomer and crosslinker) were also transparent from lack
of a porous structure. The most opaque mixtures were judged to have formed the most porous
monolithic structures; these occurred when the total porogen content was 60-70% and the
EDMA crosslinker accounted for at least 15% of the mixture.
Using these results, another series of mixtures containing the same components was
prepared, placed in 3D printed microfluidic channels for polymerization and imaged with SEM
(Figure 3.2). From the formation and flow properties of these monoliths, several observations
can be made. First, monoliths that contained a higher porogen (1-dodecanol and cyclohexanol)
content had higher flow rates than those with lower porogen content: the flow rates of the
monoliths shown in Figure 3.2A-B were slower than those in Figure 3.2C-D, which were slower
than those in Figure 3.2E-F. This meant that after polymerization was complete, it was more
difficult to clear the unpolymerized material from the monoliths in Figure 3.2A-B than those in
Figure 3.2E-F. Thus, those low-porogen-content monoliths (Figure 3.2A-B) were judged too
dense for use in SPE experiments.
A second observation from the Figure 3.2 images is distinct morphological differences
when the entire porogen content is comprised of 1-dodecanol (Figure 3.2, right column) instead
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Figure 3.2. SEM images of monoliths in 3D printed microfluidic channels. The monolith
formulations consist of 1% DMPA initiator in a mixture of OMA, EDMA, 1-dodecanol, and
cyclohexanol. (A-F) Monoliths in which the OMA:EDMA ratio was maintained at 1:1 while the
OMA+EDMA:porogen ratio was varied. (G-L) Monoliths in which the porogen content was
maintained at 65% total while the OMA:EDMA ratio was varied. (M) Table containing the
monolith composition for each of the SEM images.
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of if the mixture also contains 10% cyclohexanol (Figure 3.2, left column). I expected that the
use of only 1-dodecanol would result in a greater number of smaller pores whereas the addition
of cyclohexanol would result in fewer, but larger pores due to greater solubility of the OMA
monomer in dodecanol.38 However, these images suggest that the effects of these porogens may
be more complex; morphological differences from porogen content, while significant, did not
follow a simple trend.
A further observation from Figure 3.2G-L is the effect of maintaining constant porogen
content while changing the ratio of OMA to EDMA (monomer to crosslinker). Figure 3.2G-H
shows, similar to the microcentrifuge tube experiments described earlier, that monolith formation
is inconsistent when there is not enough crosslinker present in the mixture. Thus, these images
show that the monoliths are dense in some regions while other areas lack a monolith structure. It
can also be observed that as the crosslinker concentration increases, the monolith pore and
nodule sizes also increase (compare Figure 3.2I-J with K-L). This is likely because the greater
number of reactive groups in EDMA draws the polymerizable units in the mixture into a larger,
more rigid structure than when a higher percentage of OMA is present. These results indicate
that the nodule and pore sizes, and thus the total surface area of the monolith, are tunable by
changing the ratio of polymerizable groups in the monomer and crosslinker components.
These SEM results confirmed that several mixtures were good candidates for performing
SPE. Specifically, those monolith mixtures shown in Figure 3.2C, F, J, and L appeared to be
most promising, with good morphology and high surface area. To simplify formulations, the
mixture from Figure 3.2C was excluded as it required two porogens. The remaining three
monoliths were tested using a simple SPE experiment. I found that the vacuum-driven flow rate
through monoliths as shown in Figure 3.2F was too high for efficient extraction to occur.
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Although a smaller pressure drop might be able to slow the flow rate enough to correct this, no
additional experiments were performed with this mixture. Extraction was also inefficient for the
monolith mixture shown in Figure 3.2L, likely due to the low percentage of OMA in this
formulation; the monolith was not hydrophobic enough to effectively extract ferritin, a model
PTB protein biomarker.
The 15% OMA, 20% EDMA, and 65% 1-dodecanol monolith formulation was used in
initial SPE experiments. Although the flow rate and hydrophobicity of this monolith were
sufficient for extraction of ferritin, it did not allow for selective elution of excess fluorescent dye
prior to the biomarker. For example, flow of just 30% ACN led to partial elution of ferritin.
These results indicated that a more hydrophobic monolith was needed to retain all PTB
biomarkers, particularly the smaller peptides. Since increasing the OMA percentage
detrimentally altered the monolith morphology, instead, the OMA in the monolith from Figure
3.2J was replaced with LMA. This change had no noticeable effect on monolith morphology
(compare Figure 3.1E with Figure 3.2J) but increased the hydrophobicity of the monolith enough
to allow for PTB biomarker SPE with selective retention and elution. This LMA monolith was
also found to have consistent attachment to the 3D printed channel surfaces (Figure 3.1D) and
was well-confined to the polymerization window (Figure 3.3A).
With a suitable monolith formulation, the 3D printed microfluidic devices were ready for
SPE experiments. In initial studies, I found that a fluorescent byproduct of Irgacure 819, the
photoinitiator used during 3D printing, was present in the devices and soluble in the ACN eluent.
This fluorescent impurity increased the background signal during point fluorescence detection
experiments; however, imaging of fluorescence on the monoliths allowed effective monitoring of
analyte present during extraction and elution without interference from the impurity.
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Figure 3.3. Images of reversed-phase LMA monoliths during SPE. (A) Photograph of a monolith
showing formation and confinement within the polymerization window (visible as the two dark
lines running horizontally through the image). (B) Fluorescence images of successive steps during
SPE experiments including buffer equilibration, sample loading (Alexa Fluor or ferritin), buffer
rinse, 30% ACN elution, and 90% ACN elution. Scale is the same in all images.
Using fluorescent imaging detection, the signal after the loading and elution of analytes
could be monitored. I selected ferritin as a model biomarker analyte because its large size was
expected to lead to strong retention on the reversed-phase monolith. To evaluate conditions for
on-chip labeling, Alexa Fluor dye was used as another analyte for initial comparisons. The BCB
(pH 10) used for loading also corresponds to the elution buffer of an immunoaffinity extraction
system described earlier.25 This matching of immunoaffinity eluent to SPE loading solution
should facilitate integration of these two processes in a future PTB risk diagnostic.
The rinsing and elution solvents for Alexa Fluor and Alexa Fluor-labeled ferritin were
chosen to allow for selective elution of the two analytes. Selective elution is essential for on-chip
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labeling and should also allow biomarkers to be eluted in a small-volume, concentrated plug.
Such an enriched band should help to lower limits of detection and enable heart-cut injection for
subsequent microchip electrophoresis.31,33 Similar to previous studies,33-34 I found that Alexa
Fluor could be eluted with only buffer or at low ACN concentrations. In contrast, the ferritin was
strongly retained until 90% ACN was flowed through the monolith, at which time significant
elution could be observed. Figure 3.3B shows representative images for both Alexa Fluor and
ferritin elution. In each case, almost no fluorescent signal can be seen on the monolith during the
buffer equilibration prior to sample loading. After loading, both monoliths show high fluorescent
signal. In the Alexa Fluor experiments, the fluorescent signal is removed with buffer and 30%
ACN, such that almost no fluorescent signal is visible in the image after 30% ACN flow. This
indicates limited retention of Alexa Fluor with almost no material remaining after flowing 30%
ACN. In contrast, the ferritin images show that the high fluorescent signal is maintained through
the buffer and 30% ACN steps, demonstrating that ferritin is well retained. Lastly, the
fluorescent signal on the monolith is lower after the 90% ACN elution, indicating good elution of
the analyte and selective retention of ferritin compared to Alexa Fluor dye.
To show the versatility of this SPE system for additional analytes, a panel of nine PTB
risk biomarkers (Table 3.1) was evaluated. These peptides and proteins were fluorescently
labeled off chip, loaded on reversed-phase LMA monoliths using the established conditions, and
then observed by fluorescence imaging after retention and elution. Figure 3.4A shows the
relative fluorescent signal present on the monoliths for each analyte after loading and flowing
buffer and two different percentages of ACN, demonstrating the retention and elution
characteristics of the PTB biomarkers and fluorescent label. Figure 3.4B shows the percentage of
each retained analyte eluted with 90% ACN. Of the nine proteins and peptides, four were well
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Figure 3.4 SPE of Alexa Fluor and prelabeled PTB biomarkers on LMA reversed-phase monoliths
in 3D printed microfluidic devices. (A) Normalized fluorescent signal on the monolith after the
load, buffer rinse, 30% ACN, and 90% ACN elution steps. (B) Percent of the total retained analyte
eluted with 90% ACN. Error bars represent the standard deviation of three replicates.
retained during the buffer rinse and 30% ACN flow through steps, with >60% of the total
captured material eluted during the 90% ACN step. Three additional biomarkers were
moderately retained, with >30% of the total captured material eluted with 90% ACN. The final
three analytes, Alexa Fluor, peptide 1, and defensins, were largely eluted during the buffer rinse
step, indicating that these analytes were not strongly retained on the monolith.
As the conditions for the elution of analytes from these monoliths were chosen to
selectively elute Alexa Fluor dye and retain ferritin, it is not surprising that different retention
properties were seen for other analytes. It was expected for retention to correlate with the size of
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the analyte, with large proteins well retained and small peptides having less retention. Table 3.1
shows that the panel of PTB biomarkers has more than a 100-fold range in masses and
considerable variation in hydrophobic nature. Thus, the limited retention of peptide 1 was likely
because of its small size, and the low retention of defensins was likely due to the higher relative
hydrophilicity within its amino acid sequence. However, the remaining seven biomarkers were
moderately or well retained, showing that this SPE system has potential to perform selective
extraction through retention and elution of many proteins and peptides.
With these encouraging results for SPE of prelabeled proteins and peptides, I focused on
coupling SPE with an on-chip fluorescent labeling reaction. In contrast with the previous
experiments where PTB biomarkers were fluorescently labeled overnight in microcentrifuge
tubes prior to extraction experiments, unlabeled biomarkers were loaded onto the monolith
followed by labeling with Alexa Fluor at room temperature for 30 min prior to performing the
rinsing and elution steps. Similar to Figure 3.4, Figure 3.5A shows relative fluorescence signal
from monoliths after each step in the process for all 9 biomarkers plus the fluorescent label,
whereas Figure 3.5B further shows the percentage of each retained analyte that was eluted with
90% ACN. Analysis of these elution percentages shows moderate to good selectivity for 90%
ACN elution of all nine biomarkers relative to the Alexa Fluor label, whose elution is complete
in 30% ACN. These results show the ability to perform on-chip fluorescent labeling of proteins
and peptides having a variety of masses and hydrophobicities, with selective retention relative to
the fluorescent dye. Importantly, these results also demonstrate the first use of 3D printed
devices for on-chip labeling and purification of an entire panel of PTB biomarkers. The data
further establish the ability to achieve good retention of all nine PTB biomarkers in SPE
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Figure 3.5. SPE and on-chip fluorescent labeling of PTB biomarkers on LMA reversed-phase
monoliths. (A) Normalized fluorescent signal on the monolith after loading/labeling, buffer rinse,
30% ACN, and 90% ACN elution steps. (B) Percent of the total retained analyte eluted with 90%
ACN.
combined with selective elution of excess dye prior to biomarker elution, all under identical
conditions, a key step for streamlined on-chip sample preparation.
The on-chip labeling data in Figure 3.5 also shows that, unlike for the prelabeled
biomarkers (Figure 3.4), retention for peptide 1 and defensins is significantly increased
compared to the fluorescent dye. I hypothesized that this difference was due to the longer (30
min) labeling/incubation time, which increased interaction with the reversed-phase monolith for
retention. To test the effect of the incubation time, peptide 1 prelabeled with Alexa Fluor was
loaded with a 30-min extraction period prior to rinsing and elution. This extension of the
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extraction period raised the percentage of peptide 1 eluted with 90% ACN to >25%, the same as
observed for peptide 1 during on-chip labeling experiments. Thus, retention of small or
hydrophilic analytes can be improved by increasing extraction time, further extending the utility
of this SPE system to a variety of peptide and protein analytes.
In this work, I have demonstrated the feasibility of using 3D printed microfluidic devices
to combine SPE and fluorescent labeling of nine individual analytes in a disease risk biomarker
panel. The use of 3D printing for fabrication can make such devices widely available to other
researchers. Moreover, 3D printing streamlines the integration of microfluidic assay components
such as valves and pumps39 and makes possible the combination of SPE and labeling with further
sample preparation or separation steps.25,35 Furthermore, this work is the first to evaluate the
entire panel of nine PTB biomarkers in a miniaturized assay, which constitutes an important step
toward the development of a complete PTB risk diagnostic. Finally, the ability for these
processes to be applied to analytes that have different masses or hydrophobicities demonstrates
the broad versatility of 3D printed microfluidic SPE systems for use in other peptide- and
protein-based analysis applications.
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4. ITERATIVE DEVELOPMENT OF FLUIDIC DEVICES FOR BIOLOGICAL
APPLICATIONS

4.1

Introduction
When developing a fluidic device for a biological application, several aspects should be

considered such as the material of the device. Many applications with specific compatibility or
reagent requirements are only compatible with a limited number of materials.1 A similar
consideration is the ease of fabrication. As discussed in Chapter 1.2, some microfabrication
techniques are simpler than others. However, materials that are compatible with simpler
fabrication methods may not be compatible with the application or analytical methods being
developed.2
Regardless of material and fabrication method choice, most fluidic devices require
several iterations of fabrication and testing when being developed for a new application.3 Often,
these developmental iterations will begin with a simplified design then increase in complexity to
allow relevant experimental techniques and procedures to be established in a controlled manner.
Indeed, good scientific investigations often proceed by step-by-step improvements to existing
protocols and procedures. Furthermore, incremental improvements help to establish proof of
concept, the priority and importance of experimental procedures, and efficient problem solving.3
This chapter describes two projects that involve developing fluidic devices for biological
applications. In both cases, I performed device design and fabrication at BYU, while most testing
and feedback on device performance occurred via collaboration with researchers at another
institution. Although the material and fabrication requirements of each project were different,
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both required iterative enhancements to a simple device design to improve performance and
increase the design complexity to reach a larger goal.

4.2

Device Design and Fabrication for Point-to-Point DNA Nanowire Assembly

4.2.1

Introduction
For many years, electrical components, particularly transistors, have been decreasing in

size. The miniaturization of electronics for embedded systems, memory storage devices, and
computers has become the focal point of many nanofabrication techniques.4-5 While the size
decrease to the nano-scale comes with high cost, waste, and complexity for typical top-down
fabrication methods, alternate bottom-up fabrication can avoid many of these disadvantages.6
One such bottom-up fabrication method is the use of DNA origami as a scaffold for selective
metallization to form electrical components such as wires, diodes, and transistors. This process
involves the simple, yet selective, folding of DNA scaffold and staple strands into a specific 2- or
3-dimensional shape.7-9 The origami can then be modified to form nanowires,10-11 metal-metal
junctions,12 or metal-semiconductor junctions.13-14
As research into DNA-based nanoelectronics progresses, a method is needed to
selectively connect the nanocomponents, particularly when the exact location or orientation of
these components is not predetermined. One proposed method to solve this problem involves the
integration of work previously performed in Dr. Rebecca Schulman’s lab at Johns Hopkins
University (JHU) and the Woolley lab at BYU. Such integration involves the self-assembly of a
DNA nanotube between two terminals, successful metallization of the nanotube to form a
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nanowire, and use of the connected electrodes to electrically characterize the nanowire. This
work would constitute an important contribution to self-assembled nanoelectronics.
Previous work by the Schulman lab15 has shown that it is possible to self-assemble DNA
nanotubes between two glass surfaces. In this process (Figure 4.1), glass coverslips are
separately modified with seeding solutions for DNA attachment. The two surfaces are glued
together (10 µm spacing) and filled with a DNA “tile” solution, which self-assembles to form
DNA nanotubes with selective attachment to the two seeded surfaces.

Figure 4.1. Point-to-point attachment of DNA. Glass slides are separately modified with DNA
seeds (red and blue). The glass slides are placed together with a spacer. The gap is filled with
seeding solution and the edges are glued to prevent evaporation. The glass device is incubated to
grow DNA nanotubes between the two seeded surfaces.
To further develop the JHU method for DNA nanotube growth for downstream
metallization and nanowire characterization, experimental changes need to be implemented.
First, the seeding modification for DNA nanotube growth needs to occur selectively on surfaces
other than glass. Direct attachment of the nanotube to patterned electrodes would allow for
electrical characterization of the nanowire, once formed. Next, consideration would need to be
taken during device or experimental design to allow characterization of a single nanowire.
Finally, a more controlled method of fluid input would be needed to control nanotube and
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nanowire formation; such fluid control can be easily implemented using milli- or micro-fluidic
channels.
To realize these goals, I designed and fabricated a series of millifluidic devices for DNA
surface seeding and nanotube formation. Fabrication utilized both multi-layer photolithography
and soft lithography methods. Additionally, I incorporated electrodes fabricated from two metals,
gold and nickel, as surfaces for seeding attachment and future characterization of the nanowires.
The series of fluidic devices are described in this chapter.

4.2.2

Materials and Methods
Materials. Devices were fabricated from either glass slides (75 mm x 50 mm x 1 mm)

purchased from Corning (Corning, NY) or coverslips (22 mm x 40 mm x 0.2 mm) from VWR
(Center Valley, PA). Photolithography was performed with S1805 photoresist from MicroChem
(Westborough, MA) and MF-26A developer from Dow (Midland, MI). Feature patterns on the
glass were fabricated from gold, nickel, or Sylgard 184 polydimethylsiloxane (PDMS) from
Dow. Devices were cleaned either with deionized water or methanol from Macron (Center
Valley, PA). Nanoport fittings for world-interfacing came from IDEX (Lake Forest, IL).
Fluidic Device Fabrication. Fluidic devices were fabricated using either glass slides or
coverslips by spin coating S1805 photoresist and exposing the resist through a photomask on a
Suss aligner (Corona, CA) and developing with MF-26A developer. After patterning, some
fluidic devices had 100 nm-thick gold or nickel metal deposited onto the surface using a Denton
vacuum e-beam evaporator (Moorestown, NJ) or a custom thermal evaporator, respectively.
Excess metal and photoresist were lifted off using methanol and sonication (Branson 2510, North
Olmstead, OH). If a PDMS layer was being patterned on the surface, the glass was treated to a
similar photolithography procedure followed by spin coating deposition of PDMS (10:1 base-to70

curing agent and degassed for 30 min). Coated devices were placed in a 90 °C oven for one hour
to cure. Once cooled, the PDMS could be cut using a VLS4.60 laser cutter (Universal Laser
Systems, Scottsdale, AZ) set at 40% power, 100% speed, and 500 pulses per inch, and holes
were drilled in the glass using a 1-mm diameter diamond-tipped drill bit (Drilax, Warren, NJ).
Once fabricated, fluidic devices were carefully packaged to prevent breakage and shipped to the
JHU collaborators for testing.

4.2.3

Results and Discussion
To create a fluidic device for DNA nanotube and nanowire formation and

characterization, plans were made to create electrode junctions from gold and nickel placed 4-10
µm apart and enclosed within fluidic channels (Figure 4.2). The use of these two metals would
allow each to be selectively seeded for DNA growth and, after metallization of the DNA, would
be electrically conductive for nanowire characterization. The fluidic channel enclosure would be
~1 mm x 20-50 µm to allow easy use of syringe pumps to drive fluid flow. Later, these channel
dimensions could be reduced to use less reagent. In order to allow for imaging of electrode

Figure 4.2. Schematic of the proposed fluidic device for DNA nanowire formation and
characterization. A fluidic channel is enclosed using PDMS and glass. Gold and nickel electrodes
protrude into the fluidic channels for selective DNA seeding and growth of DNA nanotubes. Each
fluidic channel contains several of these electrode junctions for multiple measurements. (A) Top
view of an electrode junction in a fluidic channel. (B) Cross-sectional view.
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junctions using the JHU confocal microscope, the top and bottom surfaces of the device would
be glass while the side walls were patterned PDMS. The use of PDMS would allow for either
permanent or reversible closure of device channel via plasma bonding or van der Waals
interactions, respectively.16 Each glass-PDMS channel would enclose a series of electrode
junctions for simultaneous experiments.
To realize the goals presented by this fluidic device conceptualization, I began by
fabricating a simple flow channel device using glass and PDMS (Figure 4.3). This device would
allow the researchers at JHU to practice in situ fabrication including attachment of Nanoport
interface connectors and reversible bonding of glass-PDMS devices. Additionally, these devices
would provide a simple system to determine appropriate flow conditions for future experiments

Figure 4.3. Microfluidic device fabrication for 3D DNA point-to-point attachment. (A) (1) A
channel (5 mm x 25 mm x 100 nm) is patterned onto a glass slide using photolithography. (2) A
4-20 µm thick layer of PDMS is spun onto the glass slide. (3) After curing, the PDMS layer only
is cut along the channel pattern using a laser cutter, allowing solvent access to the underlying
photoresist. (4) The photoresist is dissolved with methanol, lifting off the PDMS in the channel
area. Holes are drilled into the glass at the top and bottom of the channel area. (5) The PDMSpatterned glass is reversibly sealed to glass coverslips using van der Waals interactions. Nanoports
may be affixed to the openings for syringe-pump assisted fluid flow. (B-C) Devices fabricated at
BYU (steps 1-4) and assembled at JHU (step 5) show good flow of rhodamine through the channel.
Photographs were taken by Dr. Sisi Jia at JHU.
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within these fluidic systems. These simple fluidic devices were created (Figure 4.3A) using
photolithography to pattern a 1 mm x 100 nm channel-like feature on the glass with photoresist.
Next, I spin-coated a 4-20 µm layer of PDMS on top of the glass and photoresist. After curing, I
used a laser cutter to selectively cut through the PDMS surface layer without damaging the
underlying glass. This cut allowed for solvent-assisted liftoff of the PDMS within the channel
region. After holes were drilled into the glass, the devices were shipped to JHU, where my
collaborators were able to perform flow experiments with them. Figure 4.3B shows two devices
in which the JHU collaborators reversibly bound a glass coverslip to the PDMS surface, attached
a Nanoport connector, and flowed rhodamine dye through the channel.
The next step to realizing an integrated nanowire formation fluidic device was to
establish conditions for DNA seeding on gold and nickel surfaces. To test such seeding, a design
for “patch electrodes” was proposed (Figure 4.4A). These patch electrodes consist of metal
squares placed either 5 or 10 µm apart on a glass surface. These devices could then be exposed to
seeding and tile solutions for seeding of the metal surface and DNA nanotube growth. Since
gold-attachment chemistry via a thiol is well known, initial experiments used gold patch
electrode devices.
Based on the single patch electrode design (Figure 4.4A), I made two devices which
would provide 18 connection points each for DNA seeding and nanotube growth experiments on
top of 22 x 40 mm2 glass surfaces (Figure 4.4B-C). Fabrication of these devices involved
photolithography on a glass coverslip followed by 100-nm thick gold layer deposition on a
chromium adhesion layer. Excess gold could be lifted off using a combination of a solvent and
sonication. Although sonication resulted in a faster liftoff, prolonged exposure to sonication (>30
s) caused the gold patches to pit and lift off from the glass surface (Figure 4.4D). However,
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Figure 4.4. Patch electrode device designs for testing of DNA attachment and nanotube growth
on a metal surface. (A) Schematic of gold metal patch electrodes fabricated on a glass surface. The
gap between the electrodes during fabrication is either 5 or 10 µm. (B) Schematic design of zigzag patch electrodes on a glass coverslip providing 18 electrode gaps for DNA nanotube growth.
(C) Schematic design of packed patch electrodes on a glass coverslip. This design also provides
18 electrode gaps. (D) Microscope photograph of a gap between two gold electrodes (5 µm gap
spacing, light color is the gold patch electrodes, dark gray is the glass surface), showing pitting
and defects in the gold surface due to excess sonication. (E) Microscope photograph of the gap
between two gold electrodes (10 µm gap spacing) in which the electrodes are well formed. (F)
Photograph of a gold zig-zag patch electrode device. (G) Photograph of a nickel packed patch
electrode device.
shorter sonication times allowed the patch electrodes to be cleanly and quickly fabricated (Figure
4.4E-F). Building on these results with gold, nickel patch electrodes were fabricated in a similar
manner (Figure 4.4G).
Initial experiments of DNA seeding onto gold patch electrode surfaces were encouraging.
Figure 4.5 shows confocal microscope images of DNA seeds attached to the gold surfaces near
the patch electrode junction points. While a few DNA seeds are also visible on the glass surfaces,
the JHU collaborators were optimistic that gold seeding was occurring and that the seeding
process would be more selective in a fluidic device. However, they found that these devices were
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Figure 4.5. Confocal microscope images showing DNA seeded onto gold patch electrode devices.
DNA seeds are visible as in both images as blue dots and light green rods on the surface of the
device. Images obtained from Dr. Sisi Jia at JHU.
difficult to image due to the need to flip the device upside-down on the confocal microscope.
Furthermore, they found that it was difficult to replace the buffer solution in the device for DNA
nanotube growth due to liquid runoff.
To address the imaging and solvent problems associated with initial patch electrode
devices, it was determined to pattern a layer of PDMS on top of the patch electrode devices
already being used (Figure 4.6A-B). This PDMS layer would create a boundary to hold the
buffer mixtures in place over the regions of interest while also providing a way to reversibly seal
these regions for microscope imaging. Figure 4.6C shows a schematic outline of how such a
device would be utilized to perform and characterize successive steps of DNA nanotube growth.
Similar to past devices, these PDMS-patch electrode devices were fabricated using
photolithography and metal deposition/liftoff to pattern the electrodes followed by
photolithography, spin-coating, and selective laser cutting to fabricate the PDMS layer on top. A
batch of these devices was fabricated at BYU and sent to JHU for experiments. Unfortunately,
the JHU researchers were not able to successfully remove the glass coverslip and re-hydrate the
device surface after imaging (Figure 4.6C, step 4). Additionally, although several methods were
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Figure 4.6. Schematic of the addition of a PDMS layer to the patch electrode design and the
experimental procedure for DNA nanotube growth on these devices. (A-B) PDMS layer (blue)
patterned on top of patch electrode devices (see Figure 4.4). (C) Experimental process to grow
DNA nanotubes on the patch electrodes. (1) A-seeds (red) in buffer are put onto the device to seed
the metal surface. (2) A coverslip is gently pressed to the surface to prevent solvent loss. (3) The
device is imaged upside down on a confocal microscope to confirm seeding distribution. (4) The
coverslip is removed, and lost buffer is restored. (5) B-seeds (blue) are attached to the gold surface.
Steps 2-4 are repeated to check distribution. (6) Tile mixture is added to form DNA nanotubes
(green) between the A- and B-seeds. Steps 2-4 are repeated to image tube formation. Schematic
obtained from Dr. Sisi Jia at JHU.
proposed for the selective attachment of DNA seeds to nickel electrodes,17-18 successful selective
seeding procedures have yet to be established.
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4.3

Design and Fabrication of Multi-Inlet Droplet Formation Devices for Cellular Drug
Testing

4.3.1

Introduction
It is well known in medicine that a given treatment will not have the same effect on

different people.19 It has only been within the last few decades that pharmaceutical response has
been linked to the patient’s genetic makeup.20-21 The discovery of this linkage has given rise to
the potential of personalized medicine, where individual treatment options can be offered based
on the combined use of personal health history, molecular and genetic information, and general
clinical information.22 Indeed, pharmacogenomics, or the study of treatment efficiency
dependence on genetic makeup, has been hailed as one of the greatest promises for future
medicine.23-24
The implementation of pharmacogenomics into cancer treatment is both difficult and
promising. Although a tumor from a particular tissue and patient will usually share the same
mutations, the genomic makeup of cancer variants between different tissues and patients is quite
broad.25 These variations can result in a chemotherapy treatment with toxicity to both healthy
and cancer cells. However, with the correct pharmacogenomic information, treatment can be
personalized to target a specific patient’s cancer tissue rather than generalized cellular toxicity.26
The difficulty in developing a pharmacogenetic approach to cancer treatment is that it
requires extensive drug testing to be completed with only the limited number of cells provided
by a biopsy.27 To solve this problem, researchers in Dr. Christoph Merten’s lab at the European
Molecular Biology Laboratory (EMBL) have developed a PDMS microfluidic device capable of
inputting and mixing up to 16 samples and reagents (further expansion is possible) and droplet
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generation from these solutions for fast, high-throughput cancer treatment testing.27 Furthermore,
this microfluidic device can be coupled to upstream cancer cell sorting and downstream barcode
reading to further automate and further increase the throughput of drug screening.28
Like many other microfluidics researchers, those in the Merten lab found that traditional
microfabrication methods became more challenging to manufacture for future commercialization
as the complexity of the device increased (see Chapter 1.2). Having seen capabilities of the
custom 3D printer in the Nordin lab at BYU,29 the Merten group saw 3D printing as an attractive
option for future fabrication of their cancer screening devices. Thus, I had the opportunity to
work with several EMBL researchers to design and test increasingly complex 3D printed
microfluidic devices which could be used in a similar way to the aforementioned PDMS devices.
These 3D printed devices utilized all three spatial dimensions, and had 50 x 50 µm2 channels,
150-300 µm diameter pneumatic valves, and a series of interface ports to both mimic and
miniaturize the PDMS design. The devices I developed are simple and small enough to allow for
many input solutions, though additional testing and material considerations will need to be
addressed prior to full implementation.

4.3.2

Materials and Methods
Materials. Glass slides (25 mm x 75 mm x 1 mm) were purchased from VWR (Center

Valley, PA), scored into thirds, and chemically modified using a 10% solution of 3(trimethoxysilyl)propyl methacrylate from Sigma (St. Louis, MO) in toluene from Macron
(Center Valley, PA) prior to 3D printing. 3D printing resin was made from poly(ethylene glycol)
diacrylate (PEGDA; MW 250 Da) and phenylbis(2,4,6-trimethylenzoyl)phosphine oxide
(Irgacure 819) from Sigma and 2-nitrophenyl phenyl sulfide (NPS) from TCI Chemicals
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(Portland, OR). Isopropyl alcohol (IPA) and acetone were from Macron. Finally, PTFE tubing
(0.022 in ID x 0.042 in OD) from Cole Parmer (Vernon Hills, IL) was glued into 3D printed
devices using a UV curable glue (DecorRom, Shenzhen, China).
3D Printing. Using input from EMBL collaborators, a previously published microfluidic
device design27 was modified using OpenSCAD (openscad.org) into a design that could be
created with Nordin’s 3D printer. Considerations included total device size, valve structure, 3D
geometry, and chip-to-world interfacing. The designs varied in complexity, from two to five
solution input ports and from two to eight valve pneumatic control ports. All fluidic channels
were designed to be 6 pixels (46 µm) wide by 5 layers (50 µm) tall while pneumatic control
channels were 14 pixels (106 µm) wide by 7 layers (70 µm) tall. The valves were 20-40 pixels
(150-300 µm) in diameter with 5-15 µm thick membranes.
The microfluidic devices were fabricated on a custom 3D printer with a 365 nm LED
using a custom resin consisting of 1% Irgacure 819 and 2% NPS in PEGDA.29 The bulk material
of the devices consisted of 10 µm layers, exposed for 600 ms each. The 3 pixels and 3 layers
immediately surrounding fluidic channels were only exposed for a shorter 400 ms interval to
ensure that channels were void of polymerized material for easier flushing. Valve membrane
layers were 5 µm thick and were exposed for 350 ms.
After printing, the microfluidic devices were flushed to remove all unpolymerized resin
from the voids using a combination of IPA, vacuum, and up to 35 psi air. The devices were postexposed for 20-30 min using a 405 nm LED with 11 mW·cm-2 irradiance to increase device
strength and valve membrane durability.29-30 Then, devices were visually inspected with a
microscope for feature fidelity. In some cases, PTFE tubing was glued into the ports, and 15-20
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psi air was used to check valve membrane function. Finally, 3D printed devices were packaged
and shipped to EMBL for further testing.

4.3.3

Results and Discussion
As described above, the EMBL collaborators had previously developed and tested PDMS

microfluidic devices for multi-input generation of aqueous droplets separated by oil interfaces
for cancer drug testing.27 Two of their CAD designs with 4- and 8-sample input ports are shown
in Figure 4.7. In these devices, the input ports are interfaced to syringe pumps for continuous
fluid flow. The aqueous analytes flow through the device to the valve region, where each flow is
split. The direction of flow is controlled by a series of 400 µm-wide chambers or valves resting

Figure 4.7. CAD designs of PDMS microfluidic devices for the flow of cells or other analytes into
an oil medium for droplet formation. Blue corresponds to analyte entry ports and channels, purple
are Braille valve chambers, green are aqueous analyte flow channels toward the oil region, yellow
are oil flow channels and ports, and red are analyte waste channels and ports. (A) Four-input
design. (B) Eight-input design.
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on top of a Braille display with pins that can alternate pushing on the chambers to open and close
each direction to fluid flow. One direction of flow goes into a waste channel where sample exits
the device and is disposed while the other direction flows to a junction where all sample channels
are merged before joining with the oil channel where droplet formation occurs.
The transition of the Figure 4.7 designs into a 3D printing design required several
modifications. First, the build area of the 3D printer is over 10 times smaller than the
corresponding PDMS chips, which required a more compact design while still being able to
accommodate up to 16 inputs in the final integrated device. Next, the total travel distance or
channel length of each analyte needed to remain the same. In the PDMS device, several
serpentine regions were added to normalize the distance each analyte would travel through the
device. Similar accommodations were made in the 3D printed design. Finally, the PDMS device
used Braille valves to control the flow direction of the analytes. In replacement, the 3D printed
device included pneumatic valves, each requiring an interface control connection.
Due to the complexity of creating a complete multi-inlet device, similar, simplified test
devices were designed and 3D printed first. The first test devices (Figure 4.8A-B) utilized a
signal input channel which split into two directions under control by two valves. The waste
channels exiting these valves joined into a single waste port for collection. This microfluidic test
device was small enough that five units could be 3D printed simultaneously in about 30 min.
After preliminary testing, the EMBL collaborators found that it was difficult to monitor
the function of the pneumatic valves. Since the waste channels joined before exiting the device,
the EMBL researchers couldn’t always determine if the valves were successfully blocking fluid
flow in that direction. To make this monitoring easier, a second waste port and channel were
incorporated in a new design (Figure 4.8C-D). With this modification, the EMBL collaborators
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Figure 4.8. Simple devices for testing experimental conditions transitioning from PDMS devices
to 3D printed valves and channels. Devices contain pneumatic valve control lines (dark gray), two
pneumatic valves (purple), one sample input line (blue) and either one or two waste lines (red).
(A-B) Schematic and photograph of the original test device with one input and one output. (C-D)
Schematic and photograph of the modified test device with one input and two outputs.
were able to successfully flow different solutions into the device and monitor flow control by
alternating which valve was open. As a preliminary step toward creating aqueous droplets in a
future device, a droplet emulsion flow was monitored. Figure 4.9 includes several images
demonstrating good flow control in a test device. Valve actuation was used to control flow
direction and emulsion droplets were seen flowing through open channels (Figure 4.9B) and
entering through the input port (Figure 4.9C-E).
With these encouraging results, the EMBL collaborators were ready to test a more
complex, 4-valve system. These devices could include either one sample and one oil inlet or two
sample and one oil inlet (Figure 4.10A-B). For initial testing, aqueous dyes would be used in the
place of cancer or drug analytes. Similar to the 2-valve test device, fluid flow would be driven
continuously by syringe pumps, and the direction of flow would be controlled by pneumatic
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Figure 4.9. Aqueous droplet emulsion flow through a 2-valve test device. (A) Photograph of the
emulsion flow through the right-side channels while flow in left-side channels is halted by closing
the left valve. (B) Zoomed view from the red box showing stationary emulsion droplets in the
microfluidic channels. (C-E) Zoomed view of the blue box showing the movement of emulsion
droplets through the port into the microfluidic channels. Images are taken 200 ms apart. The red
circle tracks the position of a single emulsion droplet, showing fluid flow. Images obtained from
Dr. Ramesh Utharala of EMBL.
valves. Subsequently, the requested designs from EMBL (Figure 4.10A-B) were translated into
3D CAD designs (Figure 4.10C-D) and devices were 3D printed (Figure 4.10E-F).
It was anticipated that these 4-valve devices could be used to establish conditions for
droplet formation, fluid control, and mixing, but these 3D printed devices did not fully allow for
this testing. The PEGDA bulk material used for 3D printing was too hydrophilic to allow for
aqueous droplet formation. Although all channels and valves functioned as designed, the testing
was incomplete, and no droplet formation could be obtained with these microfluidic devices.
Even though droplet formation was not possible in the 4-valve devices, the EMBL
collaborators and I still chose to test the 3D printing and control of more complex designs.
Specifically, we wanted to test general flow and valve control in a 4-analyte input (in addition to
oil), 8-valve 3D printed device. Several iterations of this device, shown in Figure 4.11, were
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Figure 4.10. Four-valve devices for testing of droplet formation by combining oil and aqueous
dye flows. (A-B) Drawing of devices with labels for flow directions and fluid types. The designs
incorporate an oil input and either one or two dye inputs. (C-D) Schematics of designed devices
showing connection ports and channels for oil input (yellow), sample input (blue), pneumatic
connections (dark gray), valves (purple), droplet output (green), and waste output (red). (E-F)
Photographs of 3D printed devices.
designed and created. The fluidic portion of these devices condensed the original PDMS chip
design (Figure 4.7A) from a ~10 cm2 device with long routing channels and serpentines into a
multi-layer “plus”-shaped design that was <1 cm2 (Figure 4.11A). The fluidic and pneumatic
connection ports for this design were originally routed vertically (Figure 4.11B-C) to maintain
simplicity of channel connections and a condensed surface area. The EMBL collaborators found
it difficult to glue tubing into these ports due to their high surface density, so a second, similar
device was designed and printed wherein the fluidic and pneumatic connection ports were
located horizontally on the sides of the devices (Figure 4.11D-F). While this design addressed
the issues from the previous layout, there was still difficulty interfacing with these ports. In
response, I created deeper ports to help keep the tubing inside the prints during the gluing
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Figure 4.11. Three iterative designs for five-input (one oil, four analyte), eight-valve 3D printed
microfluidic devices. For each design, the first schematic shows only the fluidic elements including
oil inputs and channels (yellow), sample inputs and channels (blue), valves (purple), waste
channels and valves (red), and sample-to-oil connection channels (green). In the second schematic,
pneumatic valve connections are also visible (dark gray). Finally, a photograph of each type of 3D
printed device is also included. (A-C) Initial design for an eight-valve device incorporating vertical
connection ports and a plus-shaped fluidic input/output structure. (D-F) An updated design that
still uses the plus-shaped fluidic structure but incorporates a more complex pneumatic control
system to allow for horizontal connection ports. (G-I) A further improved design which rotates the
plus-shaped fluidic structure in order to simplify the arrangement of fluidic and pneumatic
connections. This design further incorporates a void region in the center of the design for ease of
sealing pneumatic flushing channels.
process; I also increased the symmetry of the connection ports to simplify user interaction
(Figure 4.11G-I). This final 8-valve design appeared to have most of the desirable features of the
PDMS devices used in former studies. To date, only limited testing has been performed for valve
function and fluid flow, but more extensive testing is anticipated in the coming months as the
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EMBL collaborators become more expert in 3D printing and are able to use hydrophobic,
biocompatible resins for the creation of their droplet microfluidic devices.

4.4
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5. CONCLUSIONS AND FUTURE WORK

5.1

PTB Biomarker Separations
Chapter 2 described the development of an electrophoretic method to separate six preterm

birth (PTB) biomarkers. The separation was an important step towards the development of a
complete PTB diagnostic and demonstrated the capability of microchip electrophoresis as a
separation and detection method for this biomarker panel. The ability to separate six protein and
peptide biomarkers ranging from 2 to 470 kDa in ~1 min shows high potential for the rapid
analysis of the entire PTB biomarker panel on a single microfluidic device. This separation was
also the first microfluidic assay to include the majority of the PTB biomarkers in a single
analysis.
While this six biomarker separation showed many important capabilities, several
improvements are needed before a complete PTB risk diagnostic can be realized including:
analysis of all nine PTB biomarkers, transition from conventional fabrication to 3D printing,
incorporation of valves and pumps for greater automation and fluidic control, and integration
with upstream sample preparation. Each of these improvements is addressed in the subsequent
paragraphs.
As noted in Chapter 2, three of the PTB biomarkers from the published panel1 were not
included in the analysis. Since publication of that work, my lab colleagues been able to form the
thrombin-antithrombin complex and perform a seven-biomarker separation.2 Additionally, other
group members are starting to perform mass spectrometric analysis on control and clinical
maternal blood serum samples to determine which defensins are relevant to PTB risk. This
testing will allow for future inclusion of the defensin biomarker in an electrophoretic separation.
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Recently, the first microchip electrophoretic separations were performed in 3D printed
microfluidic devices, including analysis of three PTB biomarkers,3 and the seven-biomarker
separation will be performed in 3D printed devices soon. This transition to 3D printed devices
allows for fast device fabrication and simple incorporation of valves and pumps for automation. I
have begun integrating these valves and pumps, but valve function in the presence of an applied
voltage was inconclusive. To allow future testing of these valves, I designed two t-shaped
electrophoresis devices: one with a valve on each arm of the device (Figure 5.1A) and the other
including these valves and a pump on the injection channel (Figure 5.1B). These designs should
allow for optimization of valve function with an applied voltage, pneumatic-pump driven
injections, and later, easier integration with upstream sample preparation methods.

Figure 5.1. Schematics for 3D printed microchip electrophoresis devices with four reservoirs
(blue), t-shaped fluidic channels (black), and pneumatic valve control channels and ports (red and
yellow). (A) Electrophoresis microchip with valves on each channel. (B) Electrophoresis
microchip with valves and a pneumatically controlled pump (green) on the injection channel. (C)
Zoomed image of the valves near the fluid channel intersection. (D) Zoomed image of the fluid
pump from the part B schematic.
Integration of sample preparation with microchip electrophoresis has been performed
previously in Woolley’s lab;4-5 however, these studies were performed in conventionally
fabricated devices and have only included one or two PTB biomarkers. Since that time, sample
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preparation has also been performed using immunoaffinity monoliths6 and reversed-phase
monoliths (Chapter 3) in 3D printed devices. These monoliths will subsequently be combined on
a single 3D printed device with an electrophoresis channel. Such a device should be capable of
performing a complete analysis of maternal blood serum and diagnosing PTB risk. It would also
have the potential to be adapted for other biomarker analyses.

5.2

Solid-Phase Extraction and On-Chip Labeling of PTB Biomarkers
The work in Chapter 3 described the development of reversed-phase monoliths in 3D

printed devices for the extraction, on-chip fluorescent labeling, and selective retention of PTB
biomarkers. The monolith formulation chosen for these experiments selectively retained the
protein and peptide biomarkers while eluting excess fluorescent dye. Despite the range of sizes
and hydrophobicities of the nine PTB biomarkers used in this study, I was able to show good
retention of seven biomarkers when sample loading was immediately followed by rinse and
elution steps. When the biomarkers incubated for 30 min after loading, all nine biomarkers were
successfully retained on the monolith. Importantly, this study demonstrated the first usage of all
nine PTB biomarkers in a microchip analysis.
One of the disadvantages of the Chapter 3 work was that all analyte detection was
performed using a fluorescent imaging system which did not allow for quantification of monolith
capacity or analyte enrichment. This limitation was due to the presence of a photopolymerization
byproduct in the bulk of the 3D printed device that interfered with the point detection system.
This byproduct appears to be from the photoinitiator in the 3D printing resin, so I developed a
new resin consisting of 0.5% avobenzone UV absorber and 2% benzoin methyl ether
photoinitiator in poly(ethylene glycol) diacrylate (PEGDA). Figure 5.2 shows 3D printed devices
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from both the normal resin (1% Irgacure 819, 2% 2-nitrophenyl phenyl sulfide in PEGDA) and
this new formulation. The new resin yields devices that are transparent and colorless while
maintaining comparable feature sizes. Although additional adjustments to the resin formulation
may be needed to increase the polymer strength, initial results are promising that these devices
could be used for point detection experiments.

Figure 5.2. Photograph of 3D printed devices printed with the (A) normal and (B) newly
formulated resins.
Similar to the electrophoretic separations described in Chapter 2, future improvements to
solid-phase extraction include increased automation via incorporation of valves and pumps and
integration with other sample preparation and separation elements. An immediate way to
increase automation is to include multiple inlet channels with corresponding valves to open and
close the channels for fluid flow (Figure 5.3A). Such a system eliminates the need for manual
replacement of solvents between each step of the analysis. Increased automation can also be
achieved by incorporating a pneumatic pump (Figure 5.3B). This pump would allow for
controlled pumping rates and times resulting in more consistent fluid flow during experiments
than can be achieved by applying vacuum. These designed valves and pumps shown in

93

Figure 5.3. Schematics of microfluidic devices to increase the automation of a solid-phase
extraction system. Devices include fluidic channels (black), fluid reservoirs (yellow), a waste port
(light gray), pneumatic valve control channels and ports (blue), and a monolith polymerization
window (red). (A) Design for a microfluidic device with five inlets that combine to flow through
a single monolith. (B) Design for a device with pneumatic pump driven flow.
Figure 5.3 will allow for easier integration of this monolith extraction system with upstream
sample preparation and downstream separation.

5.3

Fluidic Devices for DNA Nanowire Growth and Characterization
In Chapter 4.2, I described the design, fabrication, and improvement of fluidic devices for

DNA nanotube growth, metallization, and characterization. These devices utilized glass,
polydimethylsiloxane (PDMS), gold, and nickel to create a fluidic platform for DNA tiles to be
seeded and grown into nanotubes as scaffolds for nanowire formation. The fluidic devices
mainly focused on establishing initial conditions for fluidic channel formation and the selective
attachment of DNA seeds to gold and nickel electrodes for nanotube growth. The JHU
collaborators were able to successfully assemble glass-PDMS devices fabricated at BYU, seed
DNA, and image my gold “patch electrode” devices.
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While conditions for selective attachment of DNA seeds to the gold electrodes followed
well-established procedures (thiol attachment), a different method is still needed to attach DNA
seeds to nickel electrodes. As mentioned in Chapter 4.2.3, several possible methods were
proposed, but none have been tested to determine if the seeding attachment is sufficient for DNA
nanotube growth. After an appropriate method is determined, this process will be combined with
the gold electrode seeding for DNA nanotube growth between the two different electrodes. For
this experiment, I planned to fabricate patch electrode devices with half gold and the other half
nickel (Figure 5.4). Such fabrication would be performed by repeating the photolithography and
metal deposition steps described in Chapter 4.2.2 for each metal. Proper care must be taken
during photolithography to align the fabricated layers so that the desired gap between the
electrodes (5-10 µm) is obtained accurately and consistently.

Figure 5.4. Schematics of patch electrode devices with electrode junctions comprised of 5-10 µm
gaps between gold and nickel electrodes on glass slides. (A) Zig-zag patch electrode device. (B)
Packed patch electrode design.
The final integrated device for DNA nanotube growth and nanowire formation includes
gold and nickel electrode junctions within fluidic channels. My design and expected fabrication
process are shown in Figure 5.5. Each gold and nickel electrode has two external connection
points to enable testing of electrode fidelity prior to nanowire growth. Furthermore, each
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Figure 5.5. Fabrication of integrated two-metal electrode fluidic devices for DNA nanotube
growth and nanowire formation and characterization. (A) A glass slide is patterned with gold
electrodes, each with two electrical connection points and tapering to a point in the channel
regions. (B) The pattern is turned 180° and corresponding nickel electrodes are also patterned onto
the glass. (C) Finally, a smaller glass slide with fluidic channels patterned in PDMS on the surface
is bonded onto the glass-metal surface to enclose the electrode junctions.
electrode tapers to a point within the channel, which is intended to limit the number of nanowires
connecting each junction. It is anticipated that sharp tapering will only allow one nanowire to
span the gold-nickel junction, allowing electrical conductivity measurements for a single
nanowire. If realized, this work would comprise a significant contribution to the future of selfassembled nanoelectronics and the controlled placement of nanowires.

5.4

3D Printed Multi-Inlet Droplet Generator Devices
Chapter 4.3 describes a PDMS multi-inlet droplet generator device that enabled high-

throughput testing of cancer biopsy cells with a variety of drug cocktails. My work on this
project focused on the transition of such a device from PDMS soft lithography fabrication to a
96

3D printed format. Several design iterations resulted in microfluidic devices ranging from one
input and two valves up to five inputs and eight valves. Initial testing of these devices showed
good fluid flow through the channels and flow direction control using pneumatic valves.
One of the main disadvantages of the 3D printed devices was the inability to form
aqueous droplets within a hydrophobic oil phase. This was primarily due to the hydrophilic
nature of the PEGDA material that comprises the 3D printed devices. Since these devices are
also intended to perform cell sorting, resin material biocompatibility is also desirable. Since
initial fabrication of these devices, researchers at BYU have now developed a new 3D printing
resin that is biocompatible7 and are also developing hydrophobic resins for droplet microfluidics.
Another feature of these microfluidic devices that the EMBL collaborators often
struggled with was chip-to-world interfacing. These 3D printed devices had a maximum size of
12 mm x 19 mm, significantly smaller than the >4 cm2 PDMS chips that they were accustomed
to using. Additionally, the 3D printed devices had many densely packed ports that needed
external tubing affixed for fluid input and pneumatic valve control. For example, one of the 5input, 8-valve devices shown in Figure 4.11, required connections to 15 ports, each spaced ~1.6
mm apart. Additionally, the number of required connections would only increase as the number
of analyte inputs was increased. While this might be a feasible task for an experienced
researcher, this prospect could be overwhelming for 3D printing initiates.
The solution to these dense, small connection ports is to relocate the ports onto a
secondary interface chip interfaced to the primary chip via 3D printed gasket connections, which
have been developed and tested previously with high success.8 This system would allow all
fluidic and pneumatic connection ports to be placed in a separate, reusable 3D print. Although
the need to affix external tubing into a device would not be completely eliminated, an interface
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chip would allow for greater spacing between connections. Additionally, the interface chip
would be reusable for many primary chips, significantly reducing the number of times such
gluing would need to be performed.
Once sufficient preliminary work has been performed on the previously designed devices
for droplet formation for multiple analytes, the final stage of this project is to increase the
number of available input ports to include more analytes simultaneously. The published PDMS
device used by the EMBL collaborators included 16 analyte inputs (in addition to oil flow for
droplet formation).9 By comparison, the 3D printed device shown in Figure 4.11 was only able to
accommodate four analyte inputs. However, this 4-input device was designed to be easily
compounded to accommodate additional inputs.
Figure 5.6 shows a schematic of the basic “plus”-shaped design from Figure 4.11 and
schematics of how this design can be compounded for 16- and 64-input microfluidic devices.
Importantly, the 64-input device (Figure 5.6C) is shown to scale within the full print area of the
custom 3D printer (~12 mm x 19 mm). Even with the high number of inputs in this device, about

Figure 5.6. Schematics of the aqueous flow portions of multi-input droplet generator microfluidic
devices containing fluid input channels (blue), valves (purple), sample-to-oil connection channels
(green), and waste channels (red). (A) Basic device design from Figure 4.11 for a 4-input device.
(B) Integrated design for a 16-input device. (C) Device with additional integrated units to
accommodate up to 64 inputs. The design is pictured on a background to demonstrate the full print
area of the 3D printer and illustrate the space still available for oil flow or other sample preparation
elements.
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a third of the print space is available to be filled with the oil input and flow channels as well as
any additional sample preparation elements that may be desirable for an integrated analysis such
as cell sorting, filtering channels, or pumps to replace the external syringe pumps currently being
used. If such a device were implemented, it would surpass the original PDMS devices in small
size, throughput capability, and automation. It could also be easily adapted to accommodate a
variety of other drug-testing applications beyond cancer biopsies.

5.5

Concluding Remarks
Microfluidics is a powerful tool to perform analyses at lower cost, higher efficiency, or

greater automation than many benchtop instruments. The variety of microfluidic device materials
allows microfluidic applications to take advantage of desirable properties and microfabrication
methods to obtain optimal experimental results. In this dissertation, I have described four
examples of fluidic devices fabricated using hot embossing of a thermoplastic, 3D printing, and
soft lithography of PDMS. Each device has applied a different analytical method including
microchip electrophoresis, solid-phase extraction, DNA self-assembly, and droplet microfluidics.
Finally, each of the described works also has potential for use in biological assays or
bioelectronics with increased integration and automation to the current achievements.

5.6
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